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1. INTRODUCTION 
 
1 
1.1. Mesenchymal stromal cells (MSCs) 
 
Mesenchymal stromal cells (MSCs) are non-hematopoietic multipotent cells capable of 
differentiating at least along three lineages: osteoblasts, adipocytes and chondrocytes. MSCs 
belong to the stromal cells that play an important role in supporting hematopoiesis through 
their adhesion/interaction with the hematopoietic stem cells (HSCs) and secretion of 
cytokines and growth factors that are necessary for HSC differentiation (1). 
 
1.1.1. The discovery and terminology of mesenchymal stromal cells 
 
Mesenchymal stem cells have been of interest long before the term „MSC‟ came into 
existence. German pathologist Cohnheim in 1867 suggested the presence of nonhematopoietic 
stem cells in bone marrow. He described that bone marrow may be the source of fibroblasts 
that deposit collagen fibers as a part of the normal process of wound repair (2). 
The pioneering studies of differentiation potential of bone marrow cells transplants in the 
bone tissue came from Friedenstein (3). He and his coworkers (4;5) described for the first 
time formation of fibroblast colonies in monolayer cultures of cells from bone marrow and 
spleen cultures. To obtain MSCs they placed whole bone marrow in plastic culture dishes and 
after 4 hours they removed nonadherent cells. Adherent cells gave rise to typically elongated 
fibroblast cells from which on the 3
rd
-5
th
 day appear fibroblast colonies and on the 10
th
-14
th
 
day they already consisted of hundreds or thousands of cells with considerable differences in 
the shapes and in the density of individual colonies. Friedenstein demonstrated that each 
colony is derived from a single fibroblastic colony-forming cell (FCFC) or colony forming 
unit-fibroblastic (CFU-F) (6). They also showed that these ex vivo grown cells termed as 
“stromal mechanocytes” when transplanted under kidney capsule differentiated in bone tissue 
in the site of the transplantation (7). These cells were able to differentiate into mesenchymal 
cells as well as fibroblasts (8) and chondroblasts (9). Friedenstein`s observations were 
followed by other groups throughout the 1980s. 
At the beginning of the eighties, extensive in vitro studies allowed a more precise 
characterization of the MSCs. Castro-Malaspina et al. (10) suggested how progenitor cells for 
CFU-F could be selectively isolated by density gradient (density “cut”) at 1.070/cm3. 
The notion of a “stromal stem cell” was proposed for the first time by Owen (11;12), whereas 
the term human “mesenchymal stem cells” was first introduced by Caplan in 1991 to describe 
adherent, marrow-derived homogeneous cells that proliferate ex vivo and can be differentiated 
to produce multiple connective cell types (13).  
2 
As the “stem cell” label has scientific implications that may or may not be strictly correct, the 
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cell Therapy 
(ISCT) recommended a clarification of the nomenclature for these mesenchymal stem cells to 
be termed “multipotent mesenchymal stromal cells” (14). 
 
1.1.2. Sources of MSCs 
 
Adult bone marrow (BM) contains hematopoietic stem cells (HSCs) as well as non-
hematopoietic, stromal cell population. Within this stromal population reside MSCs, which 
not only support hematopoiesis but also differentiate into multiple lineages, including fat, 
bone, and cartilage. According to the CFU-F assay the frequency of progenitor cells for MSCs 
in BM aspirates is 0.001–0.01% (10;15). In newborn this frequency is 1 out 1x104; at 10 years 
of age 1 out 1x10
5
, after 30 years of life 1 out 2.5x10
5
, at 40 years of age 1 out 4x10
5
, while at 
80 years old people 1 out 2x10
6
 (16). 
In addition to the bone marrow as a major source of MSCs (4;10;15;17;18), in the last decade 
MSCs have been also isolated from many other sources such as adipose tissue (19-21), cord 
blood (22;23), amniotic fluid (24-26), human placenta (27), fetal BM and lung (28), fetal 
kidney and liver tissues (29;30), fetal skin, fascia of the abdominal rectus muscle and carotid, 
saphena vein (31), synovium (32), circulating blood (33;34), periosteum (35), cartilage (36), 
synovial fluid (37), thymus (38), dermis (39), mouse heart (40), dental pulp (41;42) and 
spleen (43). 
 
1.1.3. Definition criteria for MSCs 
 
Since MSCs are produced in different laboratories using various tissues, methods of isolation, 
expansion and characterization, the Mesenchymal and Tissue Stem Cell Committee of the 
International Society for Cell Therapy (ISCT) in order to clarify the nomenclature and to 
support the development of comparative studies between laboratories proposed the definition 
of the MSCs (44). 
The MSCs must fulfill these minimal criteria: 
1) They must adhere to plastic, 
2) They should be negative for CD34, CD45, CD14 or CD11b, CD19 or 
CD79a, HLA-DR, and positive for CD73, CD90, CD105, and  
3) They should be capable of differentiation along three lineages: chondrocyte, osteoblast and 
adipocyte. 
3 
1.1.4. Standard method for generation of MSCs 
 
The protocols for generating MSCs from different species and different sources vary. 
Standard method for generation of MSCs is the old method using plastic adherence (4). With 
difference to earlier studies nowadays instead of whole bone marrow, isolated bone marrow 
mononuclear cells using ficoll gradient are plated into plastic culture dishes to adhere for 48-
72 hours. Nonadherent cells are removed and adherent cells are cultured 10-14 days until they 
reach 70-80% confluence (45-47). Over time in culture, the non-adherent hematopoietic cells 
are washed away, resulting in small, adherent fibroblast-like cells. When cultured in medium 
MSCs display an initial lag phase of about 5 days, followed by a log phase of rapid growth for 
about 5 days, and then fall into a stationary phase (48;49).  
In vitro expansion of MSCs is conventionally achieved in medium containing fetal bovine 
serum (FBS) and is increased by addition of growth factors. However, for widespread clinical 
applications, MSCs should be cultured in FBS-free medium because of the risk of xenogenic 
contamination (50) and immunologic consequenses such as development of anti-FBS 
antibodies (51). Doucet et al. (52) used for the first time platelet lysates (PL) as an alternative 
to FBS to expand human MSCs. They demonstrated that PL-containing medium promoted 
efficient MSC expansion and MSCs cultured in the presence of PL maintained their 
osteogenic, chondrogenic, and adipogenic differentiation properties and retained their 
immunosuppressive activity. 
 
1.1.5. Heterogeneity of MSCs 
 
1.1.5.1. Heterogeneity concerning the number of progenitor cell for MSCs and their 
proliferation potential  
 
MSCs generated through plastic adherence represent a heterogeneous group of cells. The 
heterogeneity of MSCs concerning their proliferative and differentiation potential were 
reported from Friedenstein (7), who observed the differences in each culture in the shapes and 
in the density of individual colonies. Later, Owen (11) confirmed the same by describing 
CFU-F as heterogeneous stem and progenitor cells where some of them had high ability for 
self-renewal and multipotentiality whereas the other had more limited potential. The 
differences between BM donors concerning CFU-F number has been also shown by Castro-
Malaspina (10;53). 
This heterogeneity is typically exemplified by a broad range of colony sizes, representing 
varying growth rates, and different cell morphologies, ranging from fibroblast-like spindle 
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shaped cells to large flat cells colonies (48;54;55). Differences in CFU-Fs as well as in 
proliferation by the same donors of BM at the same time were observed either (48). A 
decreased number of CFU-Fs and cell proliferation of BM-MSCs with increasing age is often 
reported (56-62). Moreover, age-dependent and gender-dependent differences in the CFU-F 
frequency with a decline in the progenitor frequencies in the bone marrow of adult mice 
(mMSCs), and a lower MSC frequencies in all female donors have been reported (63). In 
contrast, other authors did not find any changes in the number of bone marrow-derived CFU-
Fs, their average size and cell density per CFU-F in the young and old persons (64). Yet, 
MSCs from old donors exhibited a decreased maximal life span compared with cells from 
young donors (24 ± 11 population doublings [PD] vs 41 ± 10 PD, P < 0.05). The mean PD 
rate was lower in old donor cells (0.05 ± 0.02 PD/day) compared with young donor cells (0.09 
± 0.02 PD/day, P < 0.05) (65). The MSCs isolated from pediatric donors reached a cumulative 
PD almost twice as high as MSCs isolated from young adult donors after 112 days, and their 
cell growth was strictly related to the donor's age (66). Phinney reported that at the first 
passage hMSCs exhibited growth rates in vitro that varied up to 12-fold between donors, but 
no correlation between growth rate and the age or gender of hBM-MSCs donors was found 
(67). 
Age-related changes in human BM-MSCs include increased oxidative damage, increased 
ROS levels and p21 and p53, suggesting a loss of MSC fitness with age (60). On contrary, 
Lund at al. reported that mesenchymal stromal cells from donors varying widely in age (8 
months to 58 years) are of equal cellular fitness after in vitro expansion under hypoxic 
conditions (68). 
Therefore, studies investigating the influence of age on MSCs are contradictory, probably due 
to differences in experimental parameters such as donor species, sex, age, cell isolation, and 
cell culture protocols. 
 
1.1.5.2. Heterogeneity concerning the differentiation potential 
 
Differentiation potential represents one of the criteria that should be fulfilled by the cells in 
order to be defined as mesenchymal stromal cells. Even though the tissue-specific 
differentiation media for MSCs are standardized, data reported on this issue are contraversial. 
According to many authors differentiation potential of MSCs may be dependent on the age of 
the donor (66;69). Osteogenic differentiation (levels of specific ALP activity) declined 
progressively (40%) with age compared to “young” and “adult” MSCs, whereas chondrogenic 
differentiation also declined in „„aged‟‟ MSCs but this did not reach significance. In addition, 
5 
adipogenic differentiation did not change significantly with age (60). According to Moerman 
et al. (70) aging activates adipogenic and suppresses osteogenic programs in mesenchymal 
marrow stroma/stem cells. In a review article Sethe et al. (71) reported that the osteogenic 
potential of human MSCs decreased with age but adipogenic properties potential was found 
either to remain unaltered or to increase with age, in contrast to mouse MSCs in which 
adipogenic potential tends to decrease (63). Other authors, however, did not observe any 
differences in mineralization matrix formation in young individuals, old individuals, and 
patients with osteoporosis (64). In line with this, it has been reported that the number of 
mesenchymal stem cells declines but neither phenotype nor osteogenic and adipogenic 
differentiation capacities changes with the age of rats (59). Moreover, there are reports which 
demonstrated gender differences concerning differentiation potential of MSCs. Katsara et al. 
(63) demonstrated for the first time that male mouse MSCs exhibit stronger differentiation 
potential towards both, the osteogenic and the adipogenic lineage. 
Previous reports described age-dependent and gender-dependent differences as to 
differentiation potential of MSCs. There are also reports which demonstrated changes in dhe 
the differentiation potential of MSCs in the same donor depending on the time of donation 
e.g. Phinney et al. reported evident differences in both growth rate and ALP activity in human 
MSC cultures established from multiple aspirates obtained over a six month period from the 
same donors. Therefore, it appears that cellular heterogeneity produced by the method of 
harvest is propagated within and among different donor populations during culture expansion 
in vitro (67) 
 
1.1.5.3. Heterogeneity of immunosupressive potential 
 
Mesenchymal stromal cells have been shown to exert an immunomodulatory potential. 
However, the reports on this potential and its mediators are controversial. As to in vitro 
studies it is quite evident that most of reports agree that MSCs show the inhibitory effect on 
proliferation of lymphocytes induced either by mitogens or allogeneic reaction ((72-76). In 
these experiments the authors demonstrated an inhibition of lymphocyte proliferation from 
10-90%. These great variations depend not only on the MNC and MSC donors but also on 
different experimental designs. Some of the authors used complete PB-MNC cell fraction, 
while the others used in their experimental setting isolated T lymphocytes or their subsets and 
dendritic cells as antigen presenting cells (74;77). There are also controversial data on the 
clinical immunosuppressive effect of MSCs. Le Blanc et al. (78) in a phase II study treated 
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successfully the acute graft versus host disease, whereas the others have not been able to 
observe such an effect (79). 
 
1.1.5.4. Heterogeneity at the clonal level 
 
Single-cell-derived (SCD) parent and doughter clones from a mesenchymal cell source, 
human umbilical cord perivascular cells (HUCPVCs), has a hierarchical schema for MSC 
self-renewal and differentiation in which a self-renewing multipotent MSC gives rise to more 
restricted self-renewing progenitors that gradually lose differentiation potential until a state of 
complete restriction to the fibroblast is reached (80). 
It is reported that about one third of single-cell derived clones differentiated into all three 
lineages. Most of the clones (60-80%) displayed an osteo-chondrogenic (OC) potential and 
none of them demonstrated a limited osteo-adipogenic (OA) or chondro-adipogenic (CA) 
differentiation potential. There were no clones found with pure chondrogenic or adipogenic 
potential either. Clones progressively lost their adipogenic and chondrogenic differentiation 
potential at increasing cell doublings (81). Russell et al. (82) investigated the relationship 
between proliferation potential of MSCs and their potency. They demonstrated that tripotent 
OAC (osteo-, adipo- and chondrogenic) clones were highly proliferative with colony-forming 
efficiencies that ranged from 35% to 90%; whereas, O clones formed colonies with an 
efficiency of 5% or less. In addition, differences in immunosuppressive capacity of MSCs 
derived from different bone marrow donors has been observed (72;73). Xu et al. (83) were the 
first to show differences in the immunosuppressive potential of mouse MSCs at the clonal 
level in vitro and in vivo. 
Therefore, to avoid or to minimize these differences and to finally obtain a homogeneous 
population of MSCs there is a need to search for novel markers which may identify progenitor 
cells for MSCs. Some of the markers used for such a purpose are described below. 
 
1.1.6. Cell surface antigens used for isolation of MSC-progenitors 
 
Despite extensive research, there is still no single cell surface marker that reliably identifies 
MSCs within the bone marrow. A series of antibodies to surface epitopes have been employed 
by several investigators as shown below, but almost none of them came into general use. 
 
STRO-1 represents the first antibody used to partially enrich CFU-Fs from human BM (84-
87). STRO-1 is also expressed on erythroblasts (84;85), and it is coexpressed by about 20% of 
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rat CD34
+
 BM-MNCs. In addition, its expression was identified in the endothelium of 
arterioles and capillaries (88). 
 
STRO-3 antibody was generated by immunization of mice with the human MSCs derived 
from STRO-1
+
 BM-MNCs. This antibody reacts with a minor subset of STRO-1
+
 cells 
contained within adult BM aspirates and does not react with CD34
+
 hematopoietic stem cells. 
STRO-3 identifies a high proportion of bone marrow stromal stem cells that possess extensive 
proliferative and multilineage differentiation capacity. Using retroviral expression cloning, it 
was found that STRO-3 binds to tissue nonspecific alkaline phosphatase, a cell surface 
glycoprotein usually associated with cells of the osteoblast lineage (89). 
 
STRO-4 antibody was generated by immunization of mice with the CD106 (VCAM-1)-
selected ovine MSCs as an immunogen. Cells isolated with STRO-4 exhibited reactivity with 
markers commonly associated with MSCs isolated by plastic adherence including CD29, 
CD44, and CD166. Moreover, when placed in inductive culture conditions in vitro, STRO-
4(+) MSCs exhibited multilineage differentiation potential and were capable of forming 
osteoblasts, adipocytes and chondrocytes. Biochemical analysis revealed that STRO-4 
identified the beta isoform of heat shock protein-90 (Hsp90beta) (90). 
CD105/SH2/endoglin (91;92) is expressed by bone marrow progenitor cells (93) and 
therefore was used to generate MSCs (94), but this antigen is also expressed on endothelial 
cells (95) and on pre–B cells (96). 
 
CD73  
The SH-3 and SH-4 monoclonal antibodies recognize epitopes present on the surface of 
human MSCs. By using SH-3 antibody, a protein of molecular weight approximately 67 kDa 
immunoprecipitated from a solubilized membrane preparation of human MSCs. Analysis of  
peptides derived from this protein by mass spectrometry and sequencing identified it as CD73 
(ecto-5‟-nucleotidase). These results indicate that both SH-3 and SH-4 epitopes are present on 
CD73, but they are distinct. CD73, present in lymphoid tissue, plays a role in the activation of 
B-lymphocytes, signal transduction in the hematopoietic compartment of bone marrow, in 
bone marrow stromal interactions and in the differentiation of MSCs (97). 
STRO-1, CD105 and CD73 antigens as markers, however, are known to be present on other 
types of BM cells and therefore are not very selective for MPCs (MSC progenitor cells). 
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SSEA-1 (Stage-specific embryonic antigen-1) identifies the most primitive mesenchymal 
progenitor cells in the adult murine bone marrow and the same subset in mesenchymal cell 
cultures. Characterization of SSEA-1+ mesenchymal cells revealed that upon purification 
these cells gave rise to SSEA-1- mesenchymal cells. Most importantly, a single-cell-derived 
population was capable of differentiating abundantly into different mesenchymal cell types in 
vivo (98). 
 
SSEA-4 (Stage-specific embryonic antigen-4) also identifies an adult mesenchymal stem cell 
and can be used for the prospective isolation of MSCs from whole human bone marrow 
aspirates in mice and humans. The MSCs generated from SSEA-4
+
 BM-MNCs were able to 
differentiate along adipocytes, osteoblasts and chondrocytes (99). 
 
D7-FIB antibody recognizes the antigen which is a fibroblast-specific molecule of yet-
unknown function. D7-FIB
+
, CD45
low
, LNGFR
+
 cells are defined as progenitor cells for 
MSCs and represent only 0.01% of BM MNCs (93). In comparison to the above mentioned 
markers, the D7-FIB molecule showed minimal co-expression on other bone marrow cells. It 
therefore appears to be superior to STRO-1 or CD105 as a marker of MPCs in bone marrow 
(93). 
 
GD2 (neural ganglioside GD2) represents a novel surface marker for the identification of 
progenitor cells for MSCs. Martinez et al. (100) demonstrated that GD2 is not only expressed 
by MSCs newly isolated from bone marrow but also by expanded MSCs in tissue culture, as 
evaluated by flow cytometry and immunocytochemistry. 
 
CD146 (MCAM, Melanoma-associated adhesion molecule) is another very useful marker for 
identification and isolation of perivascular cells (pericytes), which are supposed to be the 
ancestor cells of mesenchymal stomal cells. The evidence that multipotent mesenchymal 
stromal cells can be obtained from diverse human tissues and share functional properties and 
gene-expression profile with CD146
+
 perivascular cells demonstrates at best this relationship 
(31). 
 
CD271 antigen which is used for generation of MSCs from bone marrow (17;93;101-105), 
adipose tissue (106;107), trabecular bone (108) and amnion fluid (26). 
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1.2. CD271 antigen as a marker for isolation of progenitor cells for MSCs 
 
1.2.1. CD271 antigen  
 
CD271 (synonyms: p75NTR or LNGFR: Low-affinity Nerve Growth Factor Receptor) is the 
sixteenth member of the tumor necrosis factor receptor (TNFR) superfamily of 
transmembrane proteins. Members of the TNFR family including CD271, share homology in 
their extracellular domain which binds neurotrophins (109;110), and have a cytoplasmic death 
domain, although CD271 has a unique intracellular structure and downstream signaling 
partners. CD271 differs from other members of the TNFR receptor family in that it binds pro-
neurotrophins and mature neurotrophins and affects the growth, differentiation and death of 
the nervous system (111). 
 
1.2.2. Localization of gene for CD271 antigen 
 
The nerve growth factor receptor gene is located at human chromosome region 17q12-17q22, 
distal to the chromosome 17 breakpoint in acute leukemias (112). 
 
1.2.3 The role of CD271 antigen in the organism 
 
The interaction between nerve growth factor and nerve growth factor receptor (NGFR) plays 
an essential role in the survival and maintenance of sympathetic and sensory neurons 
(113;114). The ligands for CD271 are neurotrophins, which are nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and neurotrophin 4/5 
(NT4/5). Recent studies have provided evidence that CD271 also serves as a receptor for the 
pro-forms of these neurotrophins (111). 
 
Multiple receptor partners and functions 
 
CD271 has contradictory actions; it functions to promote cell survival or induce cell death. 
These opposing effects are mediated by the association of CD271 with a number of different 
receptor partners (111). In the absence of tyrosine kinase (Trk) neurotrophin receptor 
expression, CD271 can induce apoptosis and cell death. The signaling pathways from the 
CD271-dependent apoptotic response are incompletely understood but are thought to involve 
activation of Jun N-terminal kinase (JNK) and further downstream events such as release of 
cytochrome c and activation of caspases 9, 6 and 3 (109). In contrast to CD271-dependent 
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apoptosis, while in complex with TrkA receptor, CD271 promotes cell growth by enhancing 
the TrkA downstream signaling induced upon NGF binding (110;115). 
In summary, the outcome of CD271 activation depends on the type of ligand and the ability to 
crosslink and co-ordinate co-receptors, thereby facilitating the activation of specific signaling 
pathways (111). 
 
1.2.4. Tissue distribution of CD271 antigen 
 
CD271 antigen is expressed on neural and non-neural tissues. 
a) Neural Tissue 
Nerve growth factor (NGF) is a protein which promotes the survival and differentiation of 
sensory and sympathetic neurons in culture and plays an important role in neuronal 
development. Chesa and al. reported that human NGF-R is expressed in the peripheral nerves 
(nerve fibres, perineum), autonomic ganglia (ganglion, satellite, Schwann cells and spinal 
cord (posterior horn) and NGF-R expression changes during normal development (116). 
CD271 is widely expressed in developing neural tissue (115;117). Subpopulations of 
peripheral sympathetic and sensory neurons express varying levels of the receptor (117). 
However, in the adult, CNS expression is limited to a few restricted cell populations including 
olfactory glia, and cerebellar Purkinje neurons (118)  
 
b) Non-neural Tissue  
Outside the nervous system, NGFR (CD271) is expressed in bone marrow stroma of humans 
in vivo and in vitro (119;120), bone marrow (17;93;101-105), trabecular bone cavity (108), 
adipose tissue (106;107) and human placenta (26). p75NTR (NGFR) is expressed in 
myoblasts and developing tissues of mesenchymal origin (116;121), including hair follicles, 
limb bud fibroblasts, kidney, lung and testes (121). In mature cells, non-neural expression is 
found in endothelial cells, perivascular fibroblasts, dental pulp cells, prostate, epithelial cells 
and immune B cells (116;122). NGFR expression in malignant tumors generally parallels to 
its normal tissue distribution (116). Some human cell lines of non-neuronal cells of 
neuroectodermal origin, such as melanomas (123), neuroblastomas, meningeal cells, glial 
cells and Schwann cells (124) also express NGFR. Although little is known about the effects 
of NGF on those cells, NGFR was detected in a number of cultured cells of mesenchymal, 
epithelial, and hematopoietic derivation. lmmunohistochemical analysis showed that NGFR is 
expressed in several non-neural human tissues, and the cell types in which NGFR was found 
in derivatives from all three germ layers (116;125). 
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1.2.5. Localization of LNGFR
+
 (CD271
+
) cells in bone marrow, their morphology and 
relationship to the other cells  
 
The LNGFR stromal cells appear in the fetal bone marrow before the hematopoietic activity 
begins, originate from the vessel adventitia, and radiate in the bone marrow cavity (119). 
Using immunochemistry these authors described MSC-like cells isolated from bone marrow 
by anti-p75LNGFR antibodies that were initially shown to stain the stromal compartment of 
bone marrow. Two anti-nerve growth factor receptor (LNGFR or p75
NGFR
) antibodies, 
Me20.4 and Me821 1, label stromal cells with dendritic features in fresh smears and in 
formalin-fixed, paraffin-embedded human bone marrow. These authors described that 
LNGFR positive cells have an oval nucleus, a scanty cytoplasm with long dendrites that are in 
close contact with the hematopoietic cells, line the abluminal side of sinus endothelial cells, 
and provide the scaffold for the hematopoietic marrow. At the electron microscopy level, the 
immunogold tag labels the body and the long branching dendrites of fibroblast-like cells with 
scanty cytoplasm containing mitochondria, endoplasmic reticulum, and dense bodies. The 
LNGFR
+
 cells are positive for alkaline phosphatase, reticulin, collagen, vimentin, TE-7, and 
CD13 but negative for endothelial (vWF, CD34, Pal-E), neural (CD56, neurofilament) and 
leukocyte markers (CD45, CD68) (119). 
Caneva at al. (120) using immune-electron-microscopy described human bone marrow cells 
NGFR+ cells that were showing either a star-shape, with long and convoluted dendritic 
projections, and branching with each other to form a complex system of lacunae upon which 
hematopoietic cells were arranged. Other NGFR+ cells had an elongated spindle-like 
morphology. NGFR+ dendrites were seen in close contact with each other and with the 
different hematopoietic cells, although definite junctions were never noticed. NGFR+ 
dendrites were also observed surrounding mature plasma cells, in close apposition with 
adipocytes or surrounding bone marrow sinusoids. These findings may give some clues about 
the function of the bone marrow stromal cells, which are known to be involved in the homing 
and recirculation of hematopoietic cells. In addition, the presence and distribution of NGFR in 
the bone marrow stroma may support the recent evidence of a co-stimulatory effect of NGF in 
early hematopoiesis.  
 
1.2.6. CD271 antigen as a versatile marker for isolation of progenitor cells for MSCs  
 
It was demonstrated that the low-affinity nerve growth factor receptor (LNGFR), now 
clustered as CD271, was the most selective marker (93) for progenitor cells of MSCs. 
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Accordingly, high-level expression of CD271 on BM-MNCs was reported by independent 
studies in which this antigen was successfully used for isolation of precursor cells of MSCs 
(17;93;101-105). Interestingly, the freshly isolated p75LNGFR-fraction was approximately 
50% positive for CD133, which was down regulated to 0–1% after culture (17). In addition, 
isolation of CD271-expressing cells from the bone marrow (17), adipose tissue (106;107), 
trabecular bone (108) and human placenta (26) has been shown to yield homogeneous cell 
populations that are rich in clonogenic precursors and have a high capacity to undergo 
adipogenic and osteogenic differentiation. 
 
1.3. The role of MSCs and their therapeutic use 
 
1.3.1. MSCs in hematopoietic maintenance and engraftment 
 
The microenvironment of mammalian bone marrow is composed of several different 
elements, including macrophages, fibroblasts, adipocytes, osteoprogenitors, endothelial cells 
reticular cells and the multipotent MSCs. All these elements contribute to support 
hematopoiesis and bone homeostasis through a molecular crosstalk between hematopoietic 
stem cells (HSCs) and cells that comprise the niche, involving a large number of molecules, 
including cadherins, integrins, chemokines and cytokines (126-128). Bone marrow-derived 
MSCs play a crucial role in the development and differentiation of the lympho-hematopoietic 
system by secreting a number of growth factors and regulatory cytokines, and by promoting 
cell-to-cell interactions. Majumdar et al. (129) examined the MSC role as a stromal cell 
precursor and demonstrated that traditional marrow-derived stromal cells (MDSCs) from the 
same marrow sample are capable of supporting hematopoietic differentiation in vitro. In that 
study, RT-PCR analysis of cytokines and growth factor mRNA showed that treatment of 
MSCs with IL-1α upregulates the expression of IL-1 α, G-CS and GM-CSF compared to 
untreated MSCs. The expression of these cytokines and growth factors suggests that MSCs 
may function in hematopoiesis. The authors concluded that MSCs in long-term bone marrow 
culture (LTBMC), maintained the hematopoietic differentiation of CD34+ hematopoietic 
progenitor cells. Animal models suggest that the transplantation of healthy stromal elements, 
including MSCs may enhance the ability of the bone marrow microenvironment to support 
hematopoiesis after stem cell transplantation (130). Cotransplantation of autologous CD34+ 
hematopoietic stem cells with MSCs improved the hematopoietic engraftment in monkeys 
(131). Kim et al. (132) demonstrated that cotransplanted BM-MSCs (MSCs) with HSC 
(CD34
+
) in NOD/SCID mice, enhanced their engraftment in a MSC dose- dependent manner.  
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These experimental data, together with the known physiological role played by MSC in 
sustaining hematopoiesis, have provided the rationale for testing the capacity of these cells to 
accelerate hematologic recovery in patients receiving myeloablative therapy with HSC 
support. The first clinical trial on the use of MSC for accelerating hematologic recovery was 
conducted in women undergoing autologous transplantation for breast cancer. Twenty-eight 
breast cancer patients were infused with 1–2×106 MSC/kg, 1-24 hours after transplantation of 
CD34 cells with a rapid hematopoietic recovery occurred without any undesired reaction 
related to the infusion of MSCs (133). 
Another interesting result was obtained in a 20-year-old woman suffering from myelogenous 
leukemia. The expanded haploidentical MSCs were infused after transplantation of 
haploidentical HSCs (CD34
+
 cells) which resulted in a rapid engraftment and did not show 
acute or chronic GVDH and complete remission from leukemia (134). 
A multicenter trial explored the safety of MSC infusion also in recipients of allogeneic HSCs. 
Forty-six patients received HSCs and culture expanded MSCs from their HLA-identical 
siblings in hematologic malignancy patients. On day 0, patients were given culture-expanded 
MSCs intravenously (1.0-5.0 x10
6
/kg b.w.) 4 hours before infusion of either bone marrow or 
peripheral blood stem cells. Hematopoietic recovery was prompt for most of the patients 
(135). Consistent with this data, co-transfusion of haplo-identical hematopoietic and 
mesenchymal stromal cells to treat a patient with severe aplastic anemia improved the 
engraftment (136). In contrast, it is reported that MSCs do not support hematopoietic 
engraftment when they are cotransplanted with umbilical cord blood transplantation (UCBT) 
(137).  
Together, these data suggest that MSCs represent an important cellular component of the bone 
marrow microenvironment. 
 
1.3.2. MSCs in tissue repair and regenerative medicine 
 
The lineage commitment and transdifferentiation properties of MSCs make these stem cells 
candidates for use in repair/molecular medicine and tissue engineering. Initially, MSCs were 
thought to mediate tissue and organ repair by virtue of a multilineage differentiation potential 
that enabled them to replace damaged cells, like differentiation of the donor hMSCs after 
traumatic brain injury in adult rats in cells that also express the neuronal and astrocytic 
markers (138), or meniscus regeneration with implanted cells in osteoarthritis (OA) by locally 
delivered MSCs (139). 
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The new data, however, ascribe this effect more to the paracrine and autocrine factors, 
because MSCs secrete a variety of cytokines and growth factors that have both paracrine and 
autocrine activities. These secreted bioactive factors suppress the local immune system, 
inhibit fibrosis (scar formation) and apoptosis, enhance angiogenesis (140), and stimulate 
mitosis and differentiation of tissue-intrinsic reparative mechanisms or stem cells. These 
effects, which are referred to as trophic effects, are distinct from the direct differentiation of 
MSCs to repair the damaged tissue (141). Several studies which tested the use of MSCs in 
models of infarct (injured heart), stroke (brain), or meniscus regeneration models are viewed 
in the context of MSC-mediated trophic effects in tissue repair (15;141;142). It is now widely 
believed that in response to tissue injury, MSCs home to the site of damage (143) in mice and 
swine heart (144;145) and encourage repair processes through production of trophic factors 
(146), including growth factors, cytokines, and antioxidants (147-149). Transplantation and 
differentiation of MSCs to functional osteoblasts was demonstrated in vivo in an animal 
model and in humans, which led to treatment for osteogenesis imperfecta (150). Finally, bone 
engineering with biomaterials seeded with MSCs are effective in replacing lost bone (151). 
MSCs show plasticity, based on their ability to transdifferentiate into cells of other germ 
layers (152). It is reported that MSC are able to differentiate in neurons in mouse brain (153) 
(154), in vitro in hepatocyte- like cells (155) and in rats in muscle cells (156). Data from a 
recent study indicate that mechanically stimulated MSCs create an angiogenesis-promoting 
environment (140). 
On the basis of many reports and his own experience Prockop concludes that the primary role 
of the MSCs is to form niches for hematopoietic stem cells (paradigm I); a second paradigm is 
that the MSCs repair tissues by engraftment and differentiation to replace injured cells 
(paradigm II); and the more recent paradigm (paradigm III) is that MSCs are engaged in 
cross-talk with injured tissues and thereby generate microenvironments or 'quasi-niches' that 
enhance the tissue repair (157). 
 
1.3.3. Immunomodulatory role of MSCs 
 
Although traditionally the regenerative capacity of MSCs through their presumptive plasticity 
was seen as the driving force behind interest in these cells, their role in modulating the 
immune response is now attracting greater interest.  
T cells are a major executor of the adaptive immune response, and numerous studies have 
demonstrated that MSCs modulate the function of these cells. MSCs can exert an T cell 
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immunosuppressive effect in vitro and in vivo (158;159) by acting on all immune effectors 
(160). Low immunogenicity of MSCs might be explained with their low expression of major 
histocompatibility complex (MHC) class I antigens and lack of MHC class II and co-
stimulatory molecules such as CD40, CD80 and CD86 (73;76). Expression of MHC class II 
antigens can be induced by interferon-gamma (IFN-gamma) treatment (73;161). This is 
relevant because, in many inflammatory milieus IFN-gamma is up-regulated, which in turn 
may result in an increase in the expression of MHC class II. However, Le Blanc demonstrated 
that pretreated MSCs with IFN-gamma failed to generate a proliferative response in 
allogeneic lymphocytes (73). This property is used to expand ex vivo generated MSCs from 
either HLA-identical siblings, haploidentical donors, or third-party mismatched donors for the 
treatment of GvHD grade 2–4 (78). 
Although mostly immune privileged MSCs, may under certain conditions also be subject to 
immune rejection. Allogeneic MSCs cotransplantated with bone marrow in sublethally 
irradiated mice induce a memory T cell response resulting in rejection of an allogeneic stem 
cell graft (158;162;163). However, patients receiving treatment with allogeneic human MSCs 
did not show anti-allogeneic MSC antibody production or T cell priming (51). The lack of 
MHC class II and co-stimulatory molecules MSCs protects them from the alloreactive natural 
killer (NK)-cell-mediated lysis (164). 
In addition, human MSCs express HLA-G, a non-classical MHC class I antigen, which may 
prevent the immune response against MSCs, as shown by blocking experiments, although the 
expression seems to decrease in culture (165). The mechanisms for such positive therapeutic 
effects remain partly obscure. However, the antiproliferative properties exerted by MSCs 
inducing division arrest anergy of activated T cells in the G0 ⁄ G1 phase of the cell cycle of 
activated T cells is demonstrated (166), but not induction of apoptosis (76;77). A possible 
mechanism of MSCs on inhibition of T cell responses is that by indoleamine 2,3-dioxygenase 
(IDO)- mediated tryptophan degradation (167;168). In addition, MSCs strongly inhibit 
dendritic cells (DCs), the most potent antigen-presenting cells (APC) generated from 
peripheral blood monocytes. MSCs could suppress monocyte differentiation into DCs, 
whereby differenitated DCs expressed significantly reduced amount of CD83 antigen, 
suggesting their skew to immature status. This reaction was associated with decreased 
expression of presentation molecules (HLA-DR and CD1a) and co-stimulatory molecules 
(CD80 and CD86) and down-regulated IL-12 secretion by monocytes were also observed 
(169-171). Moreover, prostaglandin E2 (PGE2) directly added to cultures of monocytes 
blocked their differentiation toward DCs in a manner similar to MSCs (172). 
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MSCs can produce a shift from DC1 to DC2 by decreasing TNF-alpha secretion, which leads 
to a reduced number of IFN-gamma-producing Th1 cells (74), and by inducing DCs to secrete 
IL-10, which favours IL-4-producing Th2 cells and regulatory T cells (74). Spaggiari and al. 
(168) showed that MSCs not only inhibit the interleukin-2 (IL-2) induced NK proliferation 
but also prevent the induction of cytotoxic cells by down-regulation of activating receptors 
(NKp30, NKp44, and NKG2D) on the surface of NK cells. Moreover, indoleamine 2,3-
dioxygenase (IDO) and prostaglandin E2 (PGE2) represent key mediators of the MSC-induced 
inhibition of NK cells. Interestingly, MSCs inhibited interleukin-2 (IL-2)–induced NK-cell 
proliferation, contrary to the fact that activated NK cells could kill MSCs (173). 
MSCs inhibit T cell proliferation by releasing soluble factors such as TGF-β, IGF; VEGF, 
HGF, NO, IL-10 and PGE2. Production of nitric oxide (NO) by mouse MSCs has been shown 
to be involved in suppression of Stat5 phosphorylation and T cell proliferation (174). On the 
other hand, T regulatory cell population generated in the presence of MSCs in MLR was 
similar to that generated in the absence of MSCs (74). Some of interactions between MSCs 
and immune cells as well as soluble factors that mediate their immunosuppressive effects are 
shown in Figure 1. 
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Figure 1. Proposed mechanisms of action of MSCs. 
MSCs mediate their immunomodulatory effects by interacting with cells from both the innate 
(DC, pathways 2-4; NK cell, pathway 6) and adaptive immunity systems (T cell, pathways 1 
and 5). MSC inhibition of TNF-α secretion and promotion of IL-10 secretion may affect DC 
maturation state and their functional properties, resulting in skewing the immune response 
toward in an anti-inflammatory/tolerant phenotype. Alternatively, when MSCs are present an 
inflammatory microenvironment, they inhibit IFN-γ secretion from TH1 and NK cells and 
increase IL-4 secretion from TH2 cells, thereby promoting a TH1 → TH2 shift. It is likely that 
MSCs also mediate their immunomodulatory actions by direct cell-cell contact as well as by 
secreted factors. Several MSC cell-surface molecules and secreted molecules are depicted. 
CCL indicates chemokine ligand; TCR, T-cell receptor (74). 
 
 
2. HYPOTHESIS AND 
GOALS OF THE STUDY
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It is a widely accepted fact that mesenchymal stromal cells generated by plastic adherence 
(PA-MSCs) represent a heterogeneous cell population concerning their proliferative, 
differentiation, immunosuppressive and engraftment-promoting potential. So far, there are a 
few reports on proliferation and differentiation potential of CD271-MSC. However, there are 
no data on the immunosuppressive and engraftment-promoting potential of these MSCs. 
 
Consequently, the main goal of this study is to find out whether CD271-MSCs possess: 
 
a) Equal or higher proliferative potential compared to PA-MSCs in order to obtain bulk cell 
numbers for clinical transplantation 
b) Equal or higher immunosuppressive or inhibitory potential on allogeneic reaction than PA-
MSCs and  
c) Equal or higher engraftment-promoting potential in vivo than PA-MSCs 
 
An important specific goal of this study will be the investigation of the effect of CD271-
MSCs on multilineage differentiation of hematopoietic stem cells into lymphoid lineage, 
which is decisive for the clinical outcome of hematopoietic stem cell transplantation. 
 
3. MATERIALS AND METHODS 
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3.1. Materials 
 
3.1.1. Human materials 
 
3.1.1.1. Peripheral human blood 
 
Mononuclear cells were isolated from the peripheral blood of 10 healthy volunteers using a 
ficoll- density gradient, after their informed consent. These cells were used to study the 
inhibitory effect of mesenchymal stromal cells on the mitogenic or allogeneic-driven 
proliferation of mononuclear cells in the mixed lymphocyte reaction (MLR). 
 
3.1.1.2. Human bone marrow 
 
In order to generate mesenchymal stromal cells the bone marrow aspirates from the posterior 
iliac crest of 10 healthy donors (age 20–40 years) were harvested, using a protocol approved 
by the University
 
of Frankfurt Institutional Review Board (UFIRB). 
 
3.1.1.3. Mobilized CD133
+
 hematopoietic stem cells 
 
In order to study the effect of mesenchymal stromal cells on the engraftment of hematopoietic 
stem cells (CD133
+
 cells) in vivo, these cells were enriched from the apheresis product of a 
healthy donor using a protocol approved by the University of Frankfurt Institutional Review 
Board. 
 
3.1.1.4. Platelet concentrates 
 
Platelet concentrates (from 4 donors) has been purchased from the Institute of Transfusion 
and Immunohematology (Frankfurt am Main, Germany) and were used for production of 
platelet lysate.  
 
3.1.2. Experimental animals (mice) 
 
3.1.2.1. Immunodeficient NOD/SCID knock-out mice for the gamma chain of the IL-2 
 receptor (IL-2Rγnull) 
 
To study the engraftment-promoting properties of mesenchymal stromal cells in vivo, in this 
work were used five to eight week-old NOD/LtSz-scid IL2Rγnull mice that were purchased 
from Jackson Laboratories (MA, USA) and housed in microisolators under pathogen-free 
conditions. They were fed with autoclaved food and water. All experimental procedures were 
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approved by
 
the Animal Care Committee of Frankfurt am Main University and
 
the 
Regierungspräsidium Darmstadt (Gen. Nr. F. 133/06). 
 
3.1.3. Equipment  
 
Photometer, 1420 Multilabel Counter,  Perkin Elmer, Finland 
VICTOR
3 
Software      Windows Work Out 2.5 
Flow cytometer, FACS Calibur   Becton Dickinson, Heidelberg  
CellQuest software     Becton Dickinson, Heidelberg 
Cellcounter Coulter AcT-Serie     Beckmann Coulter, Irland 
Microscope Olympus CKX 41    Olympus, Japan 
iQTM 5 Multicolor Real-Time PCR detection system BIO-RAD, Munich 
iCycler iQ5 / MYiQ Optical system Software 2.0  Bio-Rad, Munich 
BD FACSArray Bioanalyzer    Becton Dickinson, Heidelberg 
FCAP Array™ software    Becton Dickinson, Heidelberg 
Fluorescence microscope    Olympus IX71, Japan 
Centrifuge Heraeus Multifuge 3SR+   Heraeus Instruments GmbH Hanau 
Centrifuge Rotina 46     Hettich, Tuttlingen 
Incubator, BBD 6220     Heraeus Instruments GmbH Hanau 
Sterile bench, Herasafe    Heraeus Instruments GmbH Hanau 
Water bath      Memmert, Schwabach 
Shaker Incubator SI100    Pharmacia Diagnostics, Staufen  
Vortexer Genie 2 
TM
      Bender & Hobein AG Zürich, Switzerland 
Pipettboy comfort     Integra Biosience, Switzerland 
Pipettes      Eppendorf, Hamburg 
Multipette
® 
plus     Eppendorf, Hamburg 
Multichanel pipette     Epperndorf, Hamburg 
MilliporeMultiScreenHTS Vacuum Manifold Millipore, Schwalbach  
Stove       Heraeus Instruments GmbH Hanau 
 
3.1.4. Plastic ware 
 
Polystyrencellcultureflasks T-25   Falcon, Becton Dickinson, Heidelberg 
Polystyrencellcutureflasks T-75   Corning,  
Polystyrencellcutureflasks T-175   Greiner, Solingen 
96-Well Mikrotiterplatte    Falcon, Becton Dickinson, Heidelberg 
Thermo-Fast 96 Semi Skirted Plate   Thermo Scientific, Dreieich 
96-Well Mikrotiterplatte, black   Corning Incorporated, USA 
96 well Filter plate for Cytokines   Millipore, Schwalbach 
48- Well-Cellculturplatte    Becton Dickinson, Heidelberg 
Strippette, 2,5,10 and 25mL    Costar, Fisher Scintific GmbH, Schwerte 
Combitips, 0,5ml und 5ml    Eppendorf, Hamburg 
Pipettips, steril 10µl,100µl,1000µl   STARLAB, Ahrensburg 
Falcon tubes 15ml, 50ml    Greiner, Solingen/Frickenhausen 
Eppendorf cups 1.5mL    Sarstedt, Neumrecht 
Cryo Tube 
TM
 Vials     Nunc, Denmark 
Sterilfilter MILLEX
®
GV, 0,22µm   MILLIPORE Corporation, USA
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S- Monovette Litium –Heparin   Sarstedt, Nümbrecht 
FACS Tubes      BD Biosciences, Heidelberg 
Petri dishes 10x15mm    Becton Dickinson, Heidelberg 
 
3.1.5. Chemicals and solutions 
 
Biocoll Separating Solution (Ficoll) 1.077  Biochrom KG, Berlin 
Ficoll 1.073      GE Healthcare, Uppsala, Sweden 
PBS Dulbecco‟s PBS     PAA Laboratories GmbH, Austria 
RPMI 1640 + glutaMAX 
TM
     GIBCO/ Invitrogen, Darmstadt. 
DMEM + glutaMAX 
TM
    GIBCO/ Invitrogen, Darmstadt 
MSCs Qualified Fetal Bovine Serum  GIBCO/ Invitrogen, Darmstadt 
Fetal Bovine Serum  (FBS)    GIBCO/ Invitrogen, Darmstadt  
Pen Strep (5000U/ml Penicillin    
+ 5000 µg/ml Streptomycin)    GIBCO/ Invitrogen, Darmstadt 
Platelet concentrate Institute of Transfusion and 
Immunohematology, Frankfurt am Main 
Heparin-Natrium 5000UI/mL   Ratiopharm, Ulm 
Human serum albumin solution   Baxter, Heidelberg 
Bovine serum albumin (BSA)   PAA Laboratories GmbH, Austria 
EDTA-Solution (0.5 M)    AppliChem GmbH, Darmstadt 
Dimethyl sulfoxide, minimum 99,5% GC  Sigma ALDRICH, Steinheim 
Trypan Blue Stain 0,4%    GIBCO/ Invitrogen Corporation,UK 
Trypsin,TrypLE
 TM
 select    GIBCO/ Invitrogen Corporation,U.K 
NH AdipoDiff Medium    Miltenyi Biotec, Bergisch Gladbach 
NH OsteoDiff Medium    Miltenyi Biotec, Bergisch Gladbach 
NH ChondroDiff Medium    Miltenyi Biotec, Bergisch Gladbach 
H2O, Ampuwa     Fresenius Kabi, Bad Homburg 
Proleukin, IL-2     PeproTech, Hamburg 
Phytohemagglutinin (PHA-P)   SIGMA, Munich 
Concanavalin A (Con-A)    SIGMA, Munich 
Pokeweed mitogen (PWM)    SIGMA, Munich 
Staphylococcal Enterotoxin B Fragment ( SEB) SIGMA, Munich 
Indomethacin      Sigma, Munich 
Collagenase      Sigma, Munich 
Krebs Ringer Bicarbonate    Sigma, Munich 
NaHCO3      Roth, Karlsruhe 
CaCl2 Anhydrous     Merck, Darmstadt 
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3.1.6. Media and buffers 
 
3.1.6.1. Culture media 
 
Serum-containing culture medium for mesenchymal stromal cells: 
Culture medium with FBS: DMEM + glutaMAX
TM
 + 10% MSCs Qualified FBS + 1% P/S 
 
Serum-free culture medium with platelet lysate (PL): 
Platelet lysates were obtained from fresh platelet concentrates of 4 donors with a 
concentration of 1x10
9
 platelets/ 1 ml suspension. Platelets were frozen in Eppendorf cups at -
80°C until use. Shortly before use platelets were thawed in a water bath at 37°C and thereafter 
centrifuged for 5 minutes at 13 000 x g. After centrifugation 50 µL supernatants were added 
to 1mL DMEM containing 5 units Heparin. On this basis the appropriate volumes of serum-
free medium for MSCs were generated: DMEM + glutaMAX
TM
 + 5% PL + 5 UI Heparin/mL 
DMEM + 1% P/S. 
 
Culture medium for peripheral blood mononuclear cells: 
This medium was prepared by supplementation of RPMI 1640 glutaMAX 
TM
 with 10% FBS 
and 1% Penicillin/Streptomycin. 
 
3.1.6.2. Freezing media 
 
1. Freezing media for MSCs 
a) DMEM + glutaMAX
TM
 + 30% FCS + 10%DMSO (for expanded MSCs with FBS) 
b) DMEM + glutaMAX
TM
 + 5% HSA + 10%DMSO (for expanded MSCs with PL) 
2. Freezing medium for PB-MNCs or BM-MNCs 
a) RPMI 1640 + glutaMAX
TM
 + 30% FBS + 10% DMSO 
 
3.1.6.3. Solution for digestion of mouse organs 
 
Krebs Ringer bicarbonate buffer: 
900mL Ampuwa water 
9.5g   Krebs Ringer bicarbonate  
1.26g   NaHCO3 
39.95 mg CaCl2 
pH=7.4 
Fill to 1000 mL with destilled water. 
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Krebs Ringer bicarbonate buffer + Collagenase 
491.6 mLKrebs Bicarbonate Buffer 
+8.33 mL 30% BSA (f.c.0.5%) 
+50 µL Collagenase 
 
3.1.7. Material for isolation of cells 
 
3.1.7.1. Material for isolation of CD271
+
BM-MNCs 
 
CD 271(LNGFR) MicroBead-Kit   Miltenyi Biotec, Bergisch Gladbach 
Magnetic field of a MACS Separator  Miltenyi Biotec, Bergisch Gladbach 
MACS MS- and LS-Columns   Miltenyi Biotec, Bergisch Gladbach 
PBS (+ 2mM EDTA + 0,5 % BSA)   PAA Laboratories GmbH, Austria 
 
3.1.7.2 Material for isolation of CD133
+ 
hematopoietic stem cells 
 
CD133 MicroBead Kit    Miltenyi Biotec, Bergisch Gladbach 
MACS Separator     Miltenyi Biotec, Bergisch Gladbach 
MACS MS- and LS-Columns   Miltenyi Biotec, Bergisch Gladbach 
PBS (+ 2mM EDTA + 0,5 % BSA)   PAA Laboratories GmbH, Austria 
 
3.1.8.  Material for staining of cells 
 
3.1.8.1. Solutions for staining of CFU-F 
 
Giemsa‟s Azur Eosin Methylenblue solution Merck, Darmstadt 
Methanol      Sigma-Aldrich, Steinheim 
 
3.1.8.2. Material for staining of osteoblasts 
 
SIGMA FAST
TM
 BCIP/NBT Substrate Tabletts Sigma, Munich 
 
3.1.8.3. Material for staining of adipocytes 
 
Oil Red O Solution     Millipore 
IC Fixation Buffer (Paraformaldehyd 4%)  e-Bioscience, Frankfurt 
 
3.1.8.4  Material for staining of chondrocytes 
 
Formalin 37%      Merck, Darmstadt 
Ethanol, 100%     Roth, Karlsruhe 
Roti-Histol       Roth, Karlsruhe 
Alcian blue-solution     Merck, Darmstadt 
Nuclear FAST RED Solution   Sigma-Aldrich, Steinheim 
Entellan      Merck, Darmstadt 
Roti
®
-Plast, Paraffin     Roth, Karlsruhe 
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3.1.9. Other kits  
 
Cell Proliferation ELISA, BrdU-Assay-Kit  Roche Applied Science, Mannheim 
Parameter
TM
 PGE2 Assay kit,   R&D Systems, Wiesbaden 
Nitric Oxide Assay Kit    BioChain Institute, USA 
Cytokine Kit, which contains two kits: 
BD
TM
 CBA Human Flex Set    BD Biosciences, Heidelberg 
for IL-2, IL-10, INF-γ, TNF, VEGF,  
Fas-ligand and Angiogenin  
Master Buffer Kit     BD Biosciences, Heidelberg 
sHLA-G ELISA     BioVendor, Heidelberg 
QIAamp DNA mini Kit    Qiagen, Hilden 
Mouse Erythrocyte Lysing Kit    R&D Systems, Wiesbaden 
 
3.1.10. Antibodies 
 
Antibodies Fluorochroms Company 
IgG1 FITC,PE,PerCP,APC BD Biosciences, Heidelberg 
CD3 FITC, PerCP, APC BD Biosciences, Heidelberg 
CD4 FITC, APC BD Biosciences, Heidelberg 
CD8 PerCP BD Biosciences, Heidelberg 
CD14 APC BD Biosciences, Heidelberg 
CD15 PE BD Biosciences, Heidelberg 
CD25 PE BD Biosciences, Heidelberg 
CD29 PE BD Biosciences, Heidelberg 
CD33 PerCP BD Biosciences, Heidelberg 
CD34 FITC BD Biosciences, Heidelberg 
CD38 APC BD Biosciences, Heidelberg 
CD44 APC BD Biosciences, Heidelberg 
CD45 FITC,PE,PerCP,APC BD Biosciences, Heidelberg 
CD45RA PerCP BD Biosciences, Heidelberg 
CD45RO PerCP BD Biosciences, Heidelberg 
CD56 PE BD Biosciences, Heidelberg 
CD62L PerCP,APC BD Biosciences, Heidelberg 
CD73 PE BD Pharmingen, Heidelberg,  
CD90 FITC BD Pharmingen, Heidelberg, 
CD105 APC Caltag, Heidelberg 
CD127 PE BD Biosciences, Heidelberg 
CD133-2 PE Miltenyi Biotec, Germany 
CD146 PE BD Biosciences, Heidelberg 
CD166 PE BD Biosciences, Heidelberg 
CD184 PerCP-Cy5 BD Biosciences, Heidelberg 
CD271 APC, PE Miltenyi Biotec, Germany 
HLA-A,B,C FITC BD Biosciences, Heidelberg 
HLA-DR PE BD Biosciences, Heidelberg 
SSEA-1 PE R&D Systems, Wiesbaden 
SSEA-4 PE R&D Systems, Wiesbaden 
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3.2. Methods 
 
3.2.1. Isolation of peripheral blood mononuclear cells (PB-MNCs) 
 
PB-MNCs were isolated using ficoll with a density gradient 1.077. One volume of peripheral 
blood was diluted with one volume PBS and thereafter layered over one volume ficoll in a 50 
ml conical tube. The tubes were centrifuged for 20 minutes at 700 x g without brake. After 
centrifugation, the PB-MNCs were collected from the interface and washed twice with PBS 
and centrifuged at 400 x g for 10 min. These cells were used at appropriate concentrations in 
MLR experiments. 
 
3.2.2. Isolation of mobilized CD133
+
 hematopoietic stem cells 
 
CD133 positive hematopoetic stem cells were isolated from PB-MNCs of a healthy donor 
with informed consent who was administered granulocyte colony-stimulating factor (G-CSF) 
to mobilize hematopoietic stem cells from bone marrow into the peripheral blood. For this 
purpose, 1x10
9
 of mobilized peripheral blood cells were diluted with PBS (1:3) and then 
proceded as for isolation of peripheral blood mononuclear cells. As the percentage of these 
cells in this sample was pretty low (about 1%) CD133
+
 cells were positively selected by 
means of immunomagnetic separation using CD133 isolation kit from Miltenyi. 
 
Principle of the MACS
®
 (Magnet-activated cell sorting) Separation 
First, the CD133
+
 cells are magnetically labeled with CD133 MicroBeads. Then, the cell 
suspension is loaded onto a MACS Column, which is placed in the magnetic field of a MACS 
Separator. The magnetically labeled CD133
+
 cells are retained within the column. After 
removing the column from the magnetic field, the magnetically retained CD133
+
 cells can be 
eluted as the positively selected cell fraction. To increase the purity, the positively selected 
cell fraction containing the enriched CD133
+
 cells is separated over a second column. These 
highly purified hematopoietic stem cells were frozen until use. After thawing they were co-
transplanted with CD271-MSCs into immunodeficient NOD/SCID mice at different ratios for 
engraftment studies. 
The CD133 enrichment procedure is presented below.  
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_______________________________________________________________________________________ 
Labeling of PB-MNCs with CD133 MicroBeads 
__________________________________________________________________________________________ 
1.  1x10
8
 PB-MNCs /300µl CliniMACS buffer   work fast and keep cell suspension  
(buffer pre-cooled on ice) 
2.  labeling    100µl FcR Blocking reagent mix well and incubate 
     100 µl CD133 MicroBeads for 30‟ at +4°C 
3. washing    10ml buffer/10
8
 cells  centrifuge 300 x g 10‟ at RT 
4. resuspend the cell pellet in 500µl buffer 
     
Magnetic separation 
 
1. Place MS column in the magnetic field of a suitable MACS Separator 
2. Prepare column by rinsing  with 500µl buffer 
3. Apply cell suspension into column 
4. Wash column 3 x 500µl. Add new buffer when the column is empty 
5. Remove column from separator and place it on a suitable collection tube 
6. Pipette 1ml buffer into the column and immediately flush out the magnetically labeled cells by  firmly 
pushing plunger into the column. 
To increase the purity of CD133
+ 
cells, enrich the eluted fraction over a second MS Column. Repeat the 
magnetic separation procedure from step 1 to step 6 by using a new column. 
__________________________________________________________________________________________ 
 
3.2.3. Isolation of BM-MNCs and their phenotypic profile 
 
Bone marrow aspirates were obtained from the posterior iliac crest of 10 healthy donors (age 
20–40 years) under whole anesthesia using a protocol approved by the University of Frankfurt 
Institutional Review Board. Approximately, 50-100 ml of bone marrow aspirates were diluted 
1:2 in PBS and after that two volumes of these samples were layered over 1 volume Ficoll 
(density: 1.073 g/ml) in a 50 ml conical tube and centrifuged at 700 x g for 30 min without 
brake. Mononuclear cells were collected from the interface, then washed twice with PBS and 
centrifuged at 400 x g for 10 min. Thereafter, mononuclear cells were counted using a cell 
counter, whereby a proportion of these cells was used for determination of phenotypic profile 
of BM-MNCs. A defined number of isolated BM-MNCs was used for generation of MSCs by 
plastic adherence (PA-MSCs) and CFU-F assay (colony forming unit- fibroblast), whereas the 
majority of them was used for CD271 enrichment. 
To determine the phenotype of CD271
+
 MSC progenitor cells, BM-MNC
 
were stained with 
monoclonal mouse anti-human
 
antibodies conjugated to fluorescein isothiocyanate, 
phycoerythrin,
 
peridinin chlorophyll protein, or allophycocyanin. The following antibodies 
were used:
 
CD13, CD14, CD15, CD29, CD34, CD44, CD45, CD73, CD90, CD105, CD146, 
CD133-2,
 
CD166, CD184, CD271, HLA-A,B,C, HLA-DR, SSEA-1 and SSEA-4. 
Fluorochrome-conjugated
 
mouse immunoglobulins were used as isotype controls. BM-MNCs 
were incubated at +4°C for 30 min. After two wash steps with PBS + 0.2% BSA the stained
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cells were analyzed on a FACSCalibur (Becton-Dickinson)
 
equipped with Macintosh software 
for data analysis (CellQuest). At least 50.000 events were acquired for each cell population 
 
3.2.4. Isolation of CD271
+
 BM-MNCs  
 
BM-MNCs were incubated with monoclonal anti-human CD271 antibody conjugated to 
allophycocyanin (APC) (isotype: mouse IgG1, clone ME 20.4) and FcR blocking reagent 
(human IgG) at 4 °C for 10 min. After washing, the cells were incubated with FcR blocking 
reagent (to block non-specific binding) and anti-APC magnetic beads for 15 min at 4°C. After 
washing cell suspension is loaded onto MACS column that is placed in the magnetic field of 
MACS Separator. The magnetically labeled CD271
+
 cells are retained on the column, 
whereas the unlabeled cells (CD271 negative) run through. After removing the column from 
the magnetic field, retained CD271 positive cells were eluted. In order to improve enrichment 
of CD271 positive cells, the eluate was once more applied to the columns. The percentages of 
CD271 positive cells in the enriched fractions were then assessed by flow cytometry. 
Recovery of the immunomagnetically separated CD271
+
 cells was calculated according to the 
following formula: Number of positive CD271
+
 cells in final fraction x percentage purity of 
CD271
+
 cells/initial number of CD271
+
 cells). 
The enriched cells were used for generation of CD271-MSCs and CFU-F assay, whereas 
CD271 depleted cells were also tested for CFU-F. 
 
The CD271 enrichment procedure is presented in details below: 
_______________________________________________________________________________________ 
Labeling with CD271 
__________________________________________________________________________________________ 
1.  1x10
7
 BM-MNCs /80µl pre-cooled buffer     work fast and keep 
(0.5%BSA/2mMEDTA/PBS)      the cells cold  
2.  labeling    10µl FcR Blocking reagent  incubate 10‟ at +4°C
     10µl CD271 antibody    
3. washing    10ml buffer/10
7
 cells        centrifuge 300 x g 10‟ at RT 
4. resuspend the cell pellet in 70µl buffer 
5. labeling    10µl FcR Blocking reagent    
     20µl Anti-APC microbeads  incubate 15‟ at +4°C 
6. washing    10ml buffer/10
7
 cells        centrifuge 300 x g 10‟ at RT 
Magnetic separation was performed as described for CD133
+
 hematopoietic stem cells. 
__________________________________________________________________________________________ 
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3.2.5. Generation of MSCs and determination of their proliferation using FBS-containing 
media and FBS-free media 
 
3.2.5.1. Generation of PA-MSCs 
 
As the progenitor cells for MSCs have the basic property to adhere to plastic we termed them 
as plastic adherent- MSCs (PA-MSCs). To generate PA-MSCs 4.2x10
6
 BM-MNCs were 
resuspended in 6 ml of either FBS or platelet lysate containing medium and plated in a T25 
(25 cm
2
) tissue culture flask with vent caps. Cells were cultured in an incubator with 5% CO2 
and 95% humidity at 37°C. After 48-72 hours, the medium containing non-adherent cells was 
removed and replaced with fresh medium. The adherent spindle-like cells were further 
cultured for 10-14 days until the cells reached about 70-80% confluence as evaluated by 
microscopy. During this time the medium is changed every 3 days (Figure 2). To detach the 
MSCs the medium was removed and the cells were washed with PBS. Then the cells were 
incubated for 6 minutes with trypsin and thereafter the effect of trypsin was neutralized with 
the culture medium. Cell suspension was centrifuged for 7 min at 350 x g and the resulting 
cell pellets were resuspended with medium and plated at a density of 2x10
3
 MSCs/cm
2
. Once 
the cells reached a 70-80% confluence the MSCs were again trypsinized and used either for 
further culture (passages) or were frozen for 24h in freezing medium at -80°C and then on the 
next day at -180°C until use. 
 
3.2.5.2. Generation of CD271-MSCs 
 
Highly purified bone marrow CD271
+
 cells (1.25 x 10
5
) were seeded in T25 (25 cm
2
) culture 
flasks with vent caps in 6 ml of either FBS-containing or FBS-free medium. The medium was 
changed after 7 days and later on every 3
rd
 day until the cells reached the confluence 70-80% 
(10-14 day). After this step the whole procedure was the same as for generation of PA-MSCs.  
Generated MSCs from CD271
+
 BM-MNSc were termed as CD271-MSC (Figure 2).  
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Figure 2. Methods for generation of mesenchymal stromal cells.  
In this figure are presented two ways of MSC generation. One proportion of the isolated bone 
marrow mononuclear cells were used for generation of MSCs by plastic adherence (PA-
MSCs) and the other part was positively enriched for CD271
+
 BM-MNCs which were then 
used for generation of CD271-MSCs. 
 
3.2.5.3. Freezing and thawing of MSCs 
 
Freezing procedure of MSCs 
After trypsinization and centrifugation the cell pellets of MSCs were resuspended in cooled 
freezing medium containing 30% FCS, 10% DMSO and 60% DMEM or 5% human serum 
albumin, 10% DMSO and 85% DMEM in serum-free cultured cells. The cells were frozen in 
a cryobox at -80°C for 24 hours and then on the next day at -180°C in liquid nitrogen. 
 
Thawing procedure of MSCs 
The MSCs were thawed quickly in the water bath at 37°C and then resuspended in cooled 
appropriate media. Thereafter, the cells were centrifuged for 7 minutes at 350xg. The 
supernatant was removed and cell pellets were resuspended in the appropriate media and the 
number of the cells was counted in a hemocytometer with trypan blue in order to evaluate cell 
viability. These cells were plated in the culture flasks and expanded as described above. 
Removal of 
nonadherent 
cells after 
48-72 h 
PA-MSCs 
 
CD271-MSCs 
MACS Method: CD271-Kit 
CD271
+
 BM-MNCs 
 
MSC confluence 
in 10-14 days 
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3.2.5.4. Proliferation of CD271-MSCs, population doublings and doubling time 
 
To evaluate the proliferative potential of MSCs, 5 x 10
4
 cells were generated from bone 
marrow of 8 donors (CD271-MSCs and PA-MSCs from the same donor) were plated in the T-
25 flasks in serum-containing (10% FBS) and MSCs of 3 donors in serum-free medium (5% 
platelet lysate). The cultured MSCs were grown until they reached 70-80% confluence from 
the first to the end of the passage 4 or 5. 
Proliferation potential of MSCs was calculated by using population doubling as presented 
below: 
 
Population Doubling (PD)  
Population doublings were calculated according to Cristofalo et al. (175) by the following 
equation:     
            
    
, where                    and                     .  
This number shows the number of cell doublings from first day of cell seeding until the day of 
cell harvest. 
 
Doubling time (DT) is the time within which the cells duplicate themselves and is calculated 
by this formula:     
       
           
, where              ,                    and 
                    .  
 
3.2.6. Determination of the frequency of progenitor cells for MSCs using Colony Forming 
Units-Fibroblast (CFU-F) assay 
 
3.2.6.1. Determination of CFU-F number in unselected BM-MNCs 
 
The frequency of progenitor cells for MSCs in unselected BM-MNCs, highly purified 
CD271
+
 BM-MNCs or negative fraction (CD271negative BM-MNCs) was assessed in a 
conventional CFU-F assay Castro-Malaspina (10). To determine frequency of progenitors for 
MSCs in freshly isolated BM-MNC, different concentrations of these cells (1x10
6
, 0.5x10
6
 
and 0.25x10
6
)
 
 were plated onto T-25 tissue culture flasks with 6 mL of the appropriate media 
(DMEM+10% MSCs-qualified FBS or DMEM+5% PL). After 7 days the culture medium 
together with nonadherent cells was removed and replaced with fresh medium. The medium 
was changed every 3
rd
 day until day 13 when the CFU-Fs were enumerated and then 
trypsinized in order to determine their cellularity. 
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Staining and enumeration of CFU-Fs 
At the end of cell culture formed colonies were gently washed twice with PBS to remove the 
residual FBS or platelet lysate and than allowed to dry for 5 minutes. Colonies were fixed 
with methanol for 3 minutes and after that it was removed and culture flasks have been dried 
and stained with diluted 1:20 Giemsa‟s azur eosin methylene blue solution for 15 minutes. 
Cell clusters containing >50 cells were scored as CFU-Fs under an inverse microscope. The 
results are presented as number of colonies per 1x10
6
 BM-MNCs. 
 
Colony-forming efficiency (CFE) was calculated using the following formula:  
        
                         
                      
       
 
3.2.6.2. Determination of CFU-F number in CD271
+
 BM-MNCs 
 
To determine the number of CFU-Fs in highly purified CD271
+
 BM-MNC different 
concentration of these cells (1x10
5
, 0,5x10
5
 and 0,25x10
5
 CD271
+ 
BM-MNCs) were seeded 
onto T-25 tissue culture flasks with 6 mL of appropriate media (DMEM+10% MSCs-
qualified FBS or DMEM+5% PL). After 7 days the culture medium together with 
nonadherent cells was removed and replaced with fresh medium. The medium was changed 
every 3
rd
 day until day 13. To stain these colonies was used the same staining procedure as for 
CFU-Fs generated by unselected BM-MNCs (3.2.6.1). 
 
3.2.6.3. Determination of CFU-F number in cell fraction depleted from CD271
+
 cells 
 
Ten million of BM-MNCs depleted from CD271
+
 cells were plated into a T-25 tissue culture 
flask with 6 ml of appropriate media (DMEM + 10% MSCs-qualified FBS or DMEM + 5% 
PL) and after 7 days the culture medium was removed and replaced with fresh medium. 
During 13 days of cell culture the medium was changed every 3
rd
 day. The staining procedure 
was the same as for CFU-F generated by unselected BM-MNCs (3.2.6.1) 
 
3.2.7. Determination of the phenotype of CD271-MSCs and PA-MSCs  
 
CD271-MSC and PA-MSC of different passages (from passage 1 to passage 4) were labelled 
with fluorochrome-conjugated mouse anti-human antibodies against non-hematopoietic 
antigens CD73, CD90, CD105, CD146, CD44, CD29, CD166, hematopoietic antigens CD45, 
CD34 and CD14 and HLA-Class I and HLA Class II molecules and incubated at 4°C for 30 
minutes. After two wash steps with PBS + 0.2% BSA the stained
 
cells were analyzed on a 
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FACSCalibur (Becton-Dickinson)
 
equipped with Macintosh software for data analysis 
(CellQuest). At least 50.000 events were acquired for each cell population 
 
3.2.8. Differentiation potential of CD271-MSCs 
 
3.2.8.1. Differentiation into osteoblasts  
 
To analyse differentiation potential of MSCs into osteoblasts, expanded MSCs in FBS-
containing or FBS-free medium of passage 2 or 4 were cultured in the special NH OsteoDiff 
medium from Miltenyi Biotec (Germany). For this purpose 4,5x10
4
 MSCs were resuspended 
in 1,5 ml in NH OsteoDiff Medium and transferred into the 35 mm diameter cell culture 
dishes. The cells were cultured in an incubator at 37°C, with 5% CO2 and 95% humidity. The 
medium was replaced every 3rd day by day 10 in culture. On day 10 osteoblasts can be 
identified by their cuboidal apparence and their association with newly synthesized new bone 
matrix. Furthemore, committed osteogenic cells are characterized by expression of high levels 
of alkaline phosphatase (AP), an enzyme that is involved in the bone matrix mineralization, 
which can be detected using SIGMA FAST™ BCIP/NBT (5-bromo-4-chloro-3-indolyl 
phosphate/nitro blue tetrazolium) tablets as an insoluble substrate for the detection of alkaline 
phosphatase. 
 
Staining steps: 
__________________________________________________________________________________________ 
- Aspirate OsteoDiff Medium from culture dishes. 
- Wash cells with 2x2 mL PBS 
- Remove PBS and incubate cells with 2 mL of pre-cooled methanol for 5 minutes at -20°C. 
- Remove methanol completely. 
- Wash cells with 2 mL of deionized H2O . 
- Remove H2O completely. 
- Add 2 mL SIGMA FAST BCIP/NTB substrate to the culture dishes and agitate slowly on a plate shaker at 
room temperature for 10 minutes.  As alkaline phosphatase expressed by osteoblasts processes the substrate, 
cells stain dark purple. 
- Aspirate the substrate solution and wash cells with 2 mL deionized H2O. 
- Keep the cells mist. If necessary add 300 µL dH2O 
- Immediately after staining examine the cells under microscope. 
__________________________________________________________________________________________ 
 
3.2.8.2. Differentiation into adipocytes 
 
The NH AdipoDiff Medium from Miltenyi Biotec (Germany) promotes differentiation and 
further maturation of MSCs into adipocytes (fat cells). For differentiation into adipocytes 
were tested both CD271-MSCs and PA-MSCs expanded in appropriate media, DMEM with 
10% FBS or 5% PL. For this purpose 7.5x10
4
 MSCs resuspended in 1.5mL NH AdipoDiff 
Medium and plated in 35 mm diameter cell culture dishes. The cells were cultured in an 
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incubator with 5% CO2 and 95% humidity. The medium was changed carfully (because 
adipocytes are very fragile) every 3
rd
 day. After 2-3 weeks, lipid vacuoles start to appear and 
on day 21 they were stained with Oil Red O solution. The staining procedure of adipocytes is 
described below: 
 
Staining steps: 
__________________________________________________________________________________________ 
- Carfully aspirate medium from culture dishes. 
- Wash cells with 2x2 mL PBS 
- Fix adipocytes by incubating in 4% paraformaldehyde for 35 minutes at room temperature. 
- Aspirate carefully fixative and rinse three times (5-10 minutes each) with 2 mL PBS 
- Aspirate and rinse with water. 
- Aspirate water and add 2 mL Oil Red O staining solution to cell culture dish and incubate at room temperature     
for 50 minutes. 
- Remove Oil Red O solution and wash the cells three times with 2 mL water. 
- Keep the cells moist. If necessary add 300 µL dH2O 
- Immediately after staining examine the cells under microscope. Adipocytes containing lipid droplets will be 
stained red by the Oil red solution. 
__________________________________________________________________________________________ 
 
3.2.8.3. Differentiation into chondrocytes  
 
To induce differentiation of MSCs into chondrocytes was used NH ChondroDiff Medium 
from Miltenyi Biotec (Germany). For this purpose, 2.5x10
5
 cells of each type of MSCs 
(CD271-MSCs and PA-MSCs) expanded either in medium with FBS or PL were resuspended 
in 1 ml of expansion medium and then placed in a 15 mL conical polypropylene tubes. 
 
Cell differentiation procedure: 
__________________________________________________________________________________________ 
- Centrifuge the cell suspension for 5 minutes at 150xg at room temperature. 
- Aspirate expansion medium completely. 
- Add 1mL of pre-warmed NH ChondroDiff Medium and resuspend cells 
- Repeat step 1. Do not resuspend cells. 
- Replace cap of the tube but do not tighten to permit the circulation of air. Place the tubes up right and incubate 
at 37°C in an incubator with 5% CO2 and humidity >95% humidity. 
- Change the medium every 3
rd
 day  
- On day 24 proceed with detection of chondrocytes. 
__________________________________________________________________________________________ 
 
Preparation of fixation and embedding reagents 
__________________________________________________________________________________________ 
1. Dilute formalin with PBS to final concentration 3.7% (neutral buffered formalin) 
2. Prepare Ethanol series (70%, 80% 96% and 100%) 
3. Heat Roti–Plast at +60°C in oven until completely melted 
__________________________________________________________________________________________ 
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Preparation slides of chondrocyte nodules 
__________________________________________________________________________________________ 
1. Aspirate NH ChondroDiff Medium from micromass culture (cells in 15 mL tubes) 
2. Wash chondrocyte nodules 1x with 1 mL PBS 
3. Fix chondrocyte nodules by immersion in neutral buffered Formalin (3.7% /PBS) overnight (6-12h) in 
room temperature with agitation (on the shaker). 
4. Place nodules in an embedding cassette with filter paper and dehydrate by applying the following 
ethanol dilution series: 
2x30 min 70% ethanol 
2x30 min. 80% ethanol  
2x30 min. 96% ethanol 
2x30 min 100% ethanol 
5. Incubate embedding casete 2x30 min in Roti-Histol. 
6. Incubate embedding casete 3x30 min in 58°C Roti-Plast. 
7. Remove chondrocyte nodules from embedding cassette and embed with pre-heated Roti-Plast in Bio-
mold. 
8. Cool overnight at -20°C 
9. Generatete 5 µm thick tissue sections using a microtome and transfer to a +40°C waterbath. 
10. Place tissue sections on HistoBond slides and incubate at 52°C for 3h. 
11. Cool to room temperature before proceeding or storage at room temperature. 
__________________________________________________________________________________________ 
 
Staining with alcian blue solution 
Alcian blue stains acid mucosubstances and acid mucines. Therefore, with this method acid 
mucosubstances are stained blue, nuclei are stained red, and cytoplasm is stained pale pink. 
 
The staining procedure: 
__________________________________________________________________________________________ 
- Deparafinize the sections using Roti-Histol and a descending ethanol dilution series and rehydrate. 
2x5 min Roti-Histol 
2x5 min 100% ethanol 
2x5 min 96% ethanol 
2x5 min 80% ethanol 
2x5 min 70% ethanol 
2x briefly rinse in deionized water. 
2x5 min in PBS 
- Incubate sections 15 min in Alcian blue solution  
- Wash sections in running tap water 3 min. 
- Rinse in distilled water 
- Incubate 10 min with Nuclear fast red solution  
- Wash sections in running tap water for 3 min. 
- Rinse in destilled water 
- Repeat ascendant ethanol series 2x and Roti histol 2x 
- Mount with Entelan  
- Microscope 
- Nuclei are red stained and acid mucosubsatances are light blue. 
__________________________________________________________________________________________ 
 
3.2.9. Transfection of MSCs with green fluorescent protein (GFP) 
 
The packaging plasmid pCMVΔR8.91 encodes the human immunodeficiency virus-1 
regulatory proteins tat and rev as well as Δplasmid pCMV gag and pol precursors. Plasmid 
pMD.G expresses vesicular stomatitis virus glycoprotein G. Pseudotyped lentiviruses were 
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produced by transient calcium-phosphate transfection of 293T cells with pCMVΔR8.91, 
pMD.G, and the lentiviral transfer vectors (SIEW) into which cDNAs encoding RhoV14 or  
C3 transferase were subcloned. Viral supernatants were collected 48–72 hours after 
transfection. Viral titers were determined on 293T cells and amounted to 0.1–1 × 108 titer 
units/ml. Lentiviral transduction of human MSCs was performed by seeding the cells in a 6-
well plate (1 × 10
5
 cells per well) in DMEM/10% FBS. The cells were allowed to attach for 
24 hours. Viral supernatants of different vectors containing multiplicity of infection 1–5 were 
added to the cells in the presence of polybrene (4μg/ml). After 24 hours, the cells were 
washed and incubated with fresh medium. The cells were split 72 hours later and expanded. 
Percentage of transduced MSCs (presence of green fluorescent protein reporter gene) was 
estimated by flow cytometry. In order to obtain a highly pure cell population of MSCS these 
cells were subsequently sorted by the FACSAria cell sorter. 
 
3.2.10. Evaluation of immunosuppressive potential of MSCs 
 
3.2.10.1. Mixed lymphocyte reaction (MLR)  
 
To study the effect of mesenchymal stromal cells on the allogeneic reaction, 1x 10
5
 peripheral 
blood mononuclear cells (PB-MNCs) from two unrelated healthy donors (5x10
4
 PBMNCs 
each) isolated using ficoll-gradient were plated in triplicates
 
 in 96-well black plates with 
opaque flat bottom in 100 µL
 
RPMI 1640 with 10% FBS per well. In the wells were added 
1x10
5
; 5x10
4
; 1x10
4 
 of lethally irradiated (30 Gy) CD271-MSC or PA-MSCs resuspended in 
100 µL of RPMI 1640 with 10%
 
FBS which generated a MSCs to PB-MNCs ratio: 1:1, 1:2 
and 1:10. In order to investigate the possible inhibitory effect of MSCs mediated by PGE2, 
some triplicates were treated with 2µL of PGE2 inhibitor indomethacin (5µM final 
concentration). The cells were incubated in an incubator at 37°C in 5% CO2 and 95% 
humidity. On day 5 the cells were labeled with 5-bromo-2‟-deoxyuridine (BrdU) and further 
incubated for another 24 hours in the incubator. The inhibitory effect of MSCs on 
proliferation of PB-MNCs on day 6 was quantified by cell proliferation assay (BrdU 
chemiluminescent assay) as Relative Light Units (RLU/sec) using the luminometer 1420 
Multilabel
 
Counter Victor
3
. In parallel, the same experimental design was set in a 48 well 
plate with a three-fold greater number of cells in order to obtain enough volume of the 
supernatants for investigation of solubile molecules (PGE2, NO, HLA-G, and cytokines) and a 
sufficient number of the cells for determination of the phenotype changes of PB-MNCs in 
MLR. On day 6 the non-adherent cells (PB-MNCs) incubated in 48 well plates were 
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resuspended in wells and then collected in 15 ml tubes and centrifuged for 10 min in 400xg. 
Supernatants were frozen at -80°C until determination of solubile molecules, whereas the cell 
pellets were used for determination of their phenotype by flow cytometry (T regs). As control 
group in each experiment were used PA-MSCs. 
 
3.2.10.2. Effect of MSCs on the mitogenic stimulation of peripheral blood mononuclear 
cells 
 
Peripheral blood mononuclear cells (PB-MNC) from healthy donors
 
were isolated by gradient 
centrifugation, plated in triplicates
 
in 96-well black plates with opaque flat bottom at a 
concentration of 10
5
 cells/100 µL
 
in RPMI 1640 with 10% FBS, and stimulated with
 
the 
following mitogens at these final concentrations: phytohemagglutinin-P (10 µg/mL),
 
concanavalin A (5 µg/mL), pokeweed mitogen (10 µg/mL),
 
and staphylococcal enterotoxin B 
(1 µg/mL) and interleukin-2 (IL-2) (500
 
IU/mL). Non-proliferative, lethally irradiated (30 Gy) 
MSC (10
5
) were resuspended in 100 µL of RPMI 1640 with 10%
 
FBS, and were added to the 
total number of responder MNCs at
 
a ratio of 1:2. Cultures were incubated at 37°C in 5% CO2
 
for 5 days, and then labelled with 5-bromo-2‟-deoxyuridine (BrdU) for 24 hours. Relative 
light units (RLU/sec)
 
were measured the following day by cell proliferation assay (described 
below) using the luminometer 1420 Multilabel
 
Counter Victor
3
 . The inhibitory effect of MSC 
on the proliferation
 
of PB-MNC was calculated using the formula: %inhibition of PB-MNCs 
proliferation = (proliferation of PB-MNCs with mitogens in the presence of 
MSCs/proliferation of PB-MNCs without MSCs) x 100. 
 
3.2.10.3 Cell proliferation assay (BrdU chemiluminescent assay) 
 
This immunoassay is based on the measurement of 5-bromo-2‟-deoxyuridine (BrdU) 
incorporation instead of thymidine during DNA synthesis in proliferating cells and represents 
a non-radioactive alternative to the [
3
H ]–thymidine incorporation assay. In this study was 
used Cell proliferation ELISA, BrdU (chemiluminescent) Kit from Roche (Roche Diagnostics 
GmbH,
 
Mannheim, Germany). Briefly, the cells are cultured in 96-well opaque flat bottom 
plates in presence of the respective cells and test substances for 5 days in an incubator with 
5% CO2 at 37°C. On day 5 BrdU is added to the cells and the cells are re-incubated for 24 h. 
During this labelling period, the pyrimidine analogue BrdU is incorporated instead of 
thymidine into the DNA of proliferating cells. After removing the culture medium the cells 
are fixed and the DNA is denatured in one step by adding FixDenat (the denaturation of the 
DNA is necessary to improve the accessibility of the incorporated BrdU for detection by the 
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antibody). The anti-BrdU-POD antibody (antibody from mouse-mouse hybrid conjugated 
with peroxidase) is added and this antibody binds to the BrdU incorporated in newly 
synthesized cellular DNA. The immune complexes are detected by the subsequent substrate 
(which contain H2O2 and luminol) reaction. POD in the presence of hydrogen peroxide 
catalyzes the oxidation of diacylhydrazides like luminol. A reaction product in an excited 
state is formed, which decays to the ground state by emitting light. Thus the signal (photons) 
generated in enzyme-catalyzed light emitting reactions (luminescence) is identical with the 
signal during radioactive decay in scintillation counting. Therefore, chemiluminescence 
detection has features and advantages comparable to radioactive methods. That means, it 
provides a rapid and constant signal over a large logarithmic measuring range. This signal is 
quantified by measuring the photons using a microplate luminometer with photomultiplier 
technology. The relative light units/second (rlu/s) directly correlates to the amount of DNA 
synthesis and hereby to the number of proliferating cells in the respective microcultures. 
 
Steps of the BrdU assay: 
__________________________________________________________________________________________ 
1. Labelling with BrdU  20 µL BrdU/well (f.c.10µM)  24h in Incubator 37°C 
2. Centrifuge the plates         10 min 400xg 
3. Remove labeling medium by flicking off 
4. Dry the plates in oven        60°C for 1h 
5. Fix the cells with 200µL/ well FixDenat      30‟ at RT 
6. Remove FixDenat by flicking off and tapping 
7. Add 100 µL/ well Antibody conjugate (BrdU POD)     90 min RT 
Monoclonal mouse-mouse antibodys conjugated with peroxidase 
8. Remove Antibody conjugate by flicking off 
9. Wash the wells 3 x with 250 µL Washing solution      5 min each 
10. Remove Washing solution by tapping 
11. Add 100 µL/ well substrate solution (containing luminol and stabilized form of H2O2) 
12. Incubate on dark on a shaker        at least 3 min. 
13. Measure the light emission of samples in a microplate luminometer with photomultiplier technology 
__________________________________________________________________________________________ 
 
 
3.2.11. Determination of prostaglandin E2 (PGE2 assay) 
 
The concentration of PGE2 in the supernatants of MLR was measured using ELISA method: 
Parameter
TM
 PGE2 Assay. For this purpose, the frozen supernatants of day 6 of MLR were 
thawed and used for PGE2 determination. Briefly, the principle of this assay is based on 
competitive binding technique in which PGE2 present in a sample competes with horseradish 
peroxidase (HRP)-labeled PGE2 for a limited number of binding sites on a mouse monoclonal 
antibody. PGE2 in the sample is allowed to bind to the antibody in the first incubation. During 
the second incubation, HRP-labeled PGE2 binds to the remaining antibody sites. Following a 
wash to remove unbound materials, a substrate solution is added to the wells to determine the 
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bound enzyme activity. The color development is stopped, and the absorbance is read at 450 
nm in a microplate reader. The intensity of the color is inversely proportional to the 
concentration of PGE2 in the sample. The standard curve was generated from 7 calibrator 
concentrations: 2500; 1250; 625; 313; 156; 78; 39 pg/mL. 
 
Assay procedure: 
__________________________________________________________________________________________ 
1. Dilute the samples with calibrator diluent 1:3. 
2. Prepare the needed number of 96 well polystyrene microplate coated with goat Anti-mouse polyclonal 
antibody.  
3. Add 150µL of Calibrator diluent RD5-56 to the non-specific binding (NSB) wells. 
4. Add 150µl of calibrator diluent to the zero standard (B0) wells.  
5. Add 50 µL of Standard and sample to remaining wells. 
6. Add 50 µL of the primary antibody solution (mouse monoclonal antibody to PGE2 with blue dye) to 
each well (excluding the NSB wells). 
7. Cover plate with sealer and incubate for 1 hour at room temperature on a microplate shaker (500 rpm). 
8. Add 50 µL of PGE2 conjugate (PGE2 conjugated to horseradish peroxydase with red dye) to each well. 
All wells except the NSB wells will now be violet in color. 
9. Cover with adhesive strip provided, and incubate for 2 hours at room temperature on the shaker. 
10. Aspirate each well and wash three times for total of four washes with 300 µl wash buffer with 
multichannel pipette. 
1. Remove completely the liquid after each wash step and after the fourth wash (last wash) invert the plate 
and blot it against clean paper towels. 
11. Add 200 µL of substrate (a mix of 1 volume hydrogen peroxide +1 volume chromogen) to each well 
and incubate for 30 minutes at room temperature protected from light. 
12. Add 100 µL Stop Solution (2N sulfuric acid) to each well and gently tap the plate to ensure thorough 
mixing. 
13. Determine the absorbance by microplate reader at 450 nm. 
 
3.2.12. Determination of solubile HLA-G (sHLA-G) 
 
sHLA-G ELISA is a sandwich enzyme immunoassay for the quantitative measurement of 
soluble forms of human leukocyte antigen-G (sHLA-G) as an immunosuppressive molecule. 
Briefly, calibrators and thawed samples of day 6 of MLR were incubated in microplate wells 
pre-coated with monoclonal anti-sHLA-G antibody. After 16-20 hours incubation and 
washing, monoclonal anti-human β2-microglobulin antibody labelled with horseradish 
peroxidase (HRP) is added to the wells and incubated for 60 minutes with captured sHLA-G. 
Following another washing step, the remaining HRP conjugate is allowed to react with the 
substrate solution (TMB, 3,3′,5,5′-tetramethylbenzidine) as a chromogen. This yields a blue 
color when oxidized, typically as a result of oxygen radicals produced by the hydrolysis of 
hydrogen peroxide by HRP. The reaction is stopped by addition of acidic solution and 
absorbance of the resulting yellow product is measured. The absorbance is proportional to the 
concentration of sHLA-G. A calibration curve is constructed by plotting absorbance values 
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against concentrations of calibrators, and concentrations of unknown samples are determined 
using this calibration curve. 
 
Steps: 
__________________________________________________________________________________________ 
1. Reconstitute calibrator with 1 ml distilled water with resulting of stock solution of 625.00 Units /ml. 
Dilute it with Dilution Buffer from 125.00units to 3.91 units (create 5 concentrations). 
2. Pipet 100 µl of calibrators, samples (diluted 1:4) and Dilution Buffer (= blank) into duplicate microplate 
wells pre-coated with monoclonal anti-sHLA antibody. 
3. Incubate plate at 2-8 °C for 16-20 hours. 
4. Wash the wells 5- times with Wash Solution (300 µl /well). After final wash, invert and tap the plate 
strongly against paper towel. 
5. Add 100 µl of Conjugate Solution (monoclonal anti-human β2- microglobulin antibody labelled with 
horseradish peroxidise (HRP)).  
6. Incubate the plate at room temperature for 1 hour by shaking ca. 300 rpm on a micropate shaker. 
7. Repeat step 4 
8. Add 100 µl of Substrate Solution (TMB-3.3‟,5,5 ‟tetramethylbenzidine) into each well. 
9. Incubate for 25 minutes at room temperature in dark 
10. Add 100 µl of Stop solution (phosphoric acid) to stop the color development. 
11. Determine the absorbance by microplate reader at 450 nm, with a reference walenlength at 630 nm. 
__________________________________________________________________________________________ 
 
3.2.13. Determination of the cytokine profile of MLR supernatants  
 
For determination of the cytokines (IL-2, IL-10, INF-γ, TNF-alpha, VEGF, Fas-ligand and 
angiogenin) in the MLR supernatants of day 6 was used BD™ Cytometric Bead Array 
(CBA), which is a flow cytometry application that allows quantification of multiple proteins 
simultaneously. The BD CBA system uses the broad dynamic range of fluorescence detection 
offered by flow cytometry and antibody-coated beads to efficiently capture analytes. Human 
Soluble Protein Flex Sets and Human Soluble Protein Master Buffer Kits employ particles 
with discrete fluorescence intensities to detect soluble analytes. The kit for estimation of 
cytokines contains 2 components:  
1. BD
TM
 CBA Human Flex Set which contains capture beads, detection reagent and standards. 
2. BD
TM
 CBA Flex Set Master Buffer Kit which contains assay reagents (Assay diluent, 
Capture bead diluent , Detection reagent diluent and wash buffer) instrument setup beads (Set 
up beads A1, A9,F1, F9; PE instrument setup bead F1 and PE positive control detector) 
configurated from compatible BD CBA Flex Sets. 
 
Principle of the test 
A BD™ CBA Human Soluble Protein Flex Set capture bead is a single bead population with 
distinct fluorescence intensity and is coated with a capture antibody specific for a soluble 
protein. The bead population is resolvable in the NIR and Red channels of a BD 
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FACSArray™ bioanalyzer or the FL3 and FL4 channels of a BD FACSCalibur™ flow 
cytometer. Each bead population is given an alphanumeric position designation indicating its 
position relative to other beads in the BD CBA Flex Set system. Beads with different 
positions can be combined in assays to create a multiplex assay. In a BD CBA Flex Set assay 
the capture bead, PE-conjugated detection reagent, and standard or test samples are incubated 
together to form sandwich complexes. Following acquisition of sample data using the flow 
cytometer, the sample results are generated in graphical and tabular formats using the FCAP 
Array™ Software. 
 
Preparation of reagents: 
__________________________________________________________________________________________ 
1. Perform instrument setup procedure. 
2. Prepare standards by mix of all lyophilized standard spheres into one tube and reconstitute them with 4 
mL of Assay diluent. This is the top Standard 2500 pg/ml. Perform a serial dilution of standards by 
dilution with Assay diluent from 1:2, 1:4, 1:32, 1:64, 1:125, 1:256 (Standards from 2500-10 pg / mL) 
3. Dilute samples 1:2 and 1:10 using Assay Diluent. 
4. Prepare Capture Beads: After vortexing for 15 seconds 50x concentrated capture beads needed for 
determination of cytokines, they are diluted 1:50 (1µL capture beads :50 µL Capture Beads diluent x 
number of tests (samples) = Mixed capture beads)  
5. Prepare PE detection reagent; Dilute PE- Detection Reagent with Detection Reagent Diluent (1:50) x 
number of tests (samples) = Mixed PE detection reagent. After preparing of standards, samples and 
reagents these reagents are pipetted into the plates 
__________________________________________________________________________________________ 
 
BD CBA Human Soluble Protein Flex Set Assay Procedure: 
__________________________________________________________________________________________ 
1. Pre- wet the clear non-sterile filter plates by adding 100 µl of wash buffer to each well. Aspirate with 
vacuum manifold, do not exceed 10‟‟ Hg of vacuum pressure for 2-10 seconds) and blot the bottom of 
the plate on paper towels. 
2. Add 50 µl of the mixed capture beads to each assay well. 
3. Add 50 µl of standard or samples and negative control (Capture Beads, Assay Diluent, PE Detection 
Reagent) to the assay wells. 
4. Mix the plate for 5 minutes using a digital shaker at 500 RPM and incubate for 1 hour at room 
temperature (RT) in dark. 
5. Add 50 µL of mixed PE Detection Reagent to each assay well. 
6. Mix the plate for 5 minutes using shaker at 500 RPM and incubate for 2 hours at RT in Dark. 
7. Aspirate the wells (do not exceed 10‟‟ Hg of vacuum pressure) until the wells are drained then blot the 
bottom of the plate on paper towels after aspiration. 
8. Pipet 150 µL Wash buffer and resuspend carefully and shake at 500 RPM for 5 minutes. 
9. Start analyzing samples on a flow cytometer.  
Following acquisition on the BD FACSArray bioanalyzer, data files are exported and analyzed using FCAP 
Array™ software, which comes installed on the BD FACSArray workstation 
____________________________________________________________________________________________________ 
 
3.2.14. Determination of nitric oxide (NO) 
 
Since NO is oxidized to nitrite and nitrate, it is a common practice to quantitate total NO2
-
/NO3
-
 as a measure for NO level. This assay was used to accurately measure NO levels in the 
supernatants of day 6 of MLR using reduction of nitrate to nitrite (improved Griess method). 
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Procedure:  
__________________________________________________________________________________________ 
1. Prepare 6 concentrations of standards: from 0-50 µM Nitrite standards diluting with distilled water in 
centrifuge tubes.  
2. Add 50 µL of glycine buffer per tube. 
3. Transfer 100 µL into wells of a clear bottom 96-well plate. 
4. Deproteination of samples: mix 100µL sample with 80 µl 75mM ZNSO4 in 1.5 eppendorf cups. If 
precipitation occurs, centrifuge 14000 rpm. 
5. Transfer supernatant to a clean tube containing 120 µl 55mM NaOH. Pellet protein precipitates again 
(dilution factor = 3) 
6. Transfer 210 µl supernatant and mix with 70µL Glycine buffer in a 1.5 mL eppendorf cup. 
7. Activation of cadmium granules (Cd). The number Cd granules to be used is 3-fold of the number of 
samples. Transfer Cd granules in a 50 mL centrifuge tube and wash them three times with water. 
Remove residual water with a pipet. 
1. Add 200µL diluted 1x Activation Buffer per granule and incubate 5 min at room temperature. Swirl the 
tube intermittently. Wash three times with water. Activated Cd should be used within 20 min. 
8. Nitrate reduction. Dry activated Cd granules on a filter paper. Add three Cd granules per sample and 
shake intermittently. Incubate 15min at room temperature. Transfer 2x100 µL samples (duplicate) into 
wells of 96-well plate. 
9. Assay: Add 50 µL reagent A to all wells and tap plate lightly to mix. Add 50 µL reagent B and mix. 
Incubate 5 min at room temperature. Read OD at 500-570 nm (peak 540nm)  
10. Calculation of results:  
Substract blank OD (150 µL Water + 50µl) and reagent A and B (step 9) from the standard values and 
plot the OD against standard concentrations. Determine the slope using linear regression fitting. The 
NO is calculated as: (OD Sample-OD Blank) x n (µM)/Slope OD Sample and OD Blank are optical 
density values of the samples and water, respectively. n is the dilution factor. 
__________________________________________________________________________________________ 
 
3.2.15. Determination of T regulatory cells (T regs) in the MLR 
 
In order to examine changes of phenotype of allogeneic cells (PB-MNCs) from two HLA-
disparate healthy persons in presence or absence of third-party lethally irradiated MSCs in 
MLR, flow cytometry analysis on day 0 and day 6 as an end-point of this assay was 
performed. In particular, in order to assess the percentage of T-regulatory cells and their 
subsets, the MNCs were stained with monoclonal antibodies against CD3, CD4, CD25 
antigens as well as CD62L and CD45RA. 
 
3.2.16. Co-transplantation of CD133
+
 hematopoietic stem cells and CD271-MSCs in 
immunodeficient NOD/SCID knock-out mice 
 
Immunodeficient NOD/SCID knock-out mice for the gamma chain of the IL-2 receptor 
(NOD/LtSz-scid IL2Rγnull) were purchased from Jackson Laboratories (MA, USA) and were 
maintained in microisolator cages under specific pathogen-free conditions. They were 
sublethally irradiated (300 cGy) 24 h before transplantation. To assist in the identification of 
human cells after transplantation into mice, green fluorescent protein (GFP) was introduced 
into passage 4 CD271-MSC and PA-MSC via lentiviral vectors. Transduced MSC, together 
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with highly enriched mobilized peripheral blood CD133
+
 cells, were administered to the 
sublethally irradiated immunodeficient mice via an injection in the lateral tail vein. The first 
group of mice was given CD133
+
 cells (1x10
5
) only, whereas the other groups were co-
transplanted with either CD271-MSC or PA-MSC at a ratio of 1:1 (10
5
 CD133
+
 cells and 10
5
 
MSC) or 1:8 (10
5
 CD133
+
 cells and 7x10
5
 MSC). All procedures were approved by the 
Animal Care Committee of Frankfurt am Main University and the Regierungspräsidium 
Darmstadt (Gen. Nr. F. 133/06).  
 
3.2.16.1. Estimation of engraftment of CD133
+
 cells in the bone marrow by 
multiparameter flow cytometric analysis 
 
Mice were sacrificed 14 weeks after co-transplantation of hematopoietic and mesenchymal 
cells. Bone marrow was obtained by flushing the cavities of the tibia and fibula bones with 
RPMI 1640 supplemented with 5% FCS using a 27 gauge-needle. Single-cell suspensions 
were treated with mouse erythrocyte lysing buffer to remove erythrocytes (Mouse Erythrocyte 
Lysing Kit) and then washed 2x with RPMI + 5% FCS. Cell pellet was washed once with 
PBS+0.5% BSA and then incubated for 30 minutes with anti-human specific antibodies 
(CD45, CD3, CD19, CD56, CD41a, and CD33) at +4°C. Thereafter, the cells were washed 
twice with PBS + 0.5% BSA and centrifuged for 10 min ar 400xg. Cell pellets were 
resuspended in 300 µL PBS + BSA 0.5% and analysed by four-color flow cytometric 
analysis. The proportion of each lineage was calculated from at least 5x10
5
 to 1x10
6
 events 
acquired using CellQuest software (Becton Dickinson, San Jose, CA, USA). 
 
3.2.16.2. Quantification of human cells in the organs of NOD/SCID mice by real-time 
PCR 
 
Fourteen weeks after transplantation, mouse organs were harvested after their sacrification. In 
order to isolate genomic DNA the organs were sliced and digested with collagenase in Krebs 
buffer for 30 minutes by rotation. Such treated tissues were thereafter homogenized using cell 
scraper through a 70 µM cell strainer. The cells which passed the strainer were washed and 
frozen in mononuclear freezing medium at -180°C until real time PCR analysis. To estimate 
human DNA in mouse organs a calibrator curve consisted of human DNA isolated from 
peripheral mononuclear cells mixed with the DNA isolated from mouse of control group  
(untreated with HSCs or MSCs) at following percentages: 10%; 1%; 0.1% and 0.01%; (from 
10
-1
 to 10
-4
) was created. Genomic DNA was isolated from 5x10
6
 human PB-MNCs with 
blood and body fluid spin protocol using the QIAamp DNA mini Kit (Qiagen, Hilden, 
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Germany), whereas for isolation of DNA from mouse cells has been used the same kit but the 
protocol for DNA isolation from tissues. 
 
The Procedure of DNA isolation from human PB-MNCs: 
__________________________________________________________________________________________ 
1. Pipet 20 µL Qiagen Protease into a 1.5 mL microcentrifuge tube. 
2. Add 200 µL sample which contain 1-5x106 cells / 200 µL PBS 
3. Add 200 µL AL buffer (Lysis buffer). Mix by pulse vortexing for 15 sec. 
4. Incubate at 56°C for 10 min. 
5. Briefly centrifuge microcentrifuge tubes 
6. Add 200 µL ethanol (96-100%) and mix by pulse vortexing for 15 sec, and thereafter centrifuge briefly 
to remove drops from inside of the lid. 
7. Apply the mixture from step 6 to the mini-spin column (which is inserted in a 2 mL collection tube), 
close the cap and centrifuge for 2 min. at 8000 RPM. Place the QIAamp Mini spin column in a clean 2 
mL collection tube and discard the collection tube containing filtrate. 
8. Add 500 µL Buffer AW (wash buffer 1) into the column. Close the cap and centrifuge at 800 rpm for 2 
minutes. Place the column in a clean 2 mL collection tube and discard the collection tube containing 
filtrate. 
9. Add 500 µL Buffer AW2 (Wash buffer 2) into the column. Close the cap and centrifuge full speed 
(13,000 rpm) for 3 min. 
10. Place the column in a new 2 mL collection tube and centrifuge at 13,000 rpm for 1 min. 
11. Place the column in a clean 1.5 mL microcentrifuge tube. Carefully open the column and add 30 µL AE 
(Elutions buffer) and incubate at RT for 5 min. 
12. Centrifuge for 1 minute at 8000 rpm.  
13. Eluted DNA concentration is measured by Eppendorf Bio Photometer. 
_________________________________________________________________________________________ 
 
The procedure of DNA isolation from mouse cells 
__________________________________________________________________________________________ 
1. After thawing of mouse cells, the cells were washed in RPMI medium followed by two washing steps 
with PBS. 
2. In cell pellets up to 10 mg were added 180 µL of ATL buffer (tissue lysis buffer) into 2 mL 
microcentrifuge tubes and 20 µl Proteinase K. Thereafter the cells were mixed by vortexing. 
3. To lyse the cells, samples were placed in a shaking water bath at 56°C and incubated overnight.  
4. Next day, the drops were removed from the inside of the lid and the tubes were briefly centrifuged  
5. 200µL of AL buffer (Lysis buffer) were added and mixed by pulse vortexing for 15 sec. 
6. To dissolve white precipitate after addition of the AL buffer the tubes were incubated at 70°C for 10 
min. 
7. The drops from the inside of the lid were removed by a brief centrifugation.  
8. Continue with the step 6 from The Procedure of isolation DNA from human PB-MNCs. 
__________________________________________________________________________________________ 
 
Real time PCR 
To correct for the quantity and quality (amplifiability) of DNA in samples, the gene encoding 
for human albumin was used (176). Sequences for TaqMan probe, forward primer, and 
reverse primer, to amplify and detect the albumin gene were: sequences for TaqMan probe: 
TGCTGAAACATTCACCTTCCATGCAGA,  
forward primer: TGAAACATACGTTCCCAAAGAGTTT and 
reverse primer: CTCTCCTTCTCAGAAAGTGTGCATAT 
For this purpose was used Absolute 
TM
QPCR ROX Mix from Thermo Scientific, which 
contained Thermo-StartTaq Polimerase, dNTP‟s including dTTP to improve reaction 
44 
sensitivity and proprietary reaction buffer that provides high sensitive, specific fluorescence 
readings for real-time and end-point analysis. In the Thermo-Fast 96- Semi Skirted Plate was 
pipetted reaction mix which was composed of following substances: 
______________________________________________________________________________________ 
      Volume    Final Concentration 
__________________________________________________________________________________________ 
ABsolute QPCR ROX Mix (2X)   10 µL   1x 
Forward primer (100 µM)    0. 08 µL   400nM 
Reverse primer (100 µM)    0, 08 µL   400 nM 
Probe (T-Sonde) (5 µM)    0, 4 µL   100 nM 
Water (PCR grade)    7, 44µL 
Tamplate DNA     2 µL   200 ng 
Total volume     20 µL 
__________________________________________________________________________________________ 
 
The products were amplified by iQ
TM
 5 Multicolor Real-Time PCR detection system, while 
the amplified products were analysed by iCycler iQ5 / MYiQ Optical system Software 2.0. 
 
QPCR thermal cycling program: Enzyme activation 
 Temp. Time Number of cycles 
Enzyme activation 95°C 15 min. 1 cycle 
Denaturation 95°C 15 sec 50 cycles 
Anealing/Extension 60°C 60 sec 
 
 
3.2.16.3. Analysis of the MSC-presence in the mouse organs by immunochistochemistry 
 
In situ analysis of mouse organs to detect resident human cells 
In order to track in vivo human GFP-positive MSC in different organs, frozen tissue sections 
were washed twice with PBS, fixed with 4% paraformaldehyde for 10 min, and permeabilized 
with 0.1% Triton X-100 in PBS containing 3% BSA. After 30 min of pre-incubation at room 
temperature, the slides were stained with an anti-GFP primary antibody (1:400, Molecular 
Probes, Invitrogen, Germany) for 60 minutes at room temperature. Unbound anti-GFP 
antibodies were removed by washing the slides three times with PBS. The samples were 
incubated with anti-rabbit Alexa Fluor 488-conjugated secondary antibodies (1:1000, 
Molecular Probes) and phycoerythrin-labeled anti-human HLA-A, HLA-B, and HLA-C 
antibodies (1:100) (BD Biosciences) for another 60 min at room temperature in the dark. 
After washing with PBS and mounting on coverslips in VectaShield mounting medium 
containing 4,6-diamino-2-phenylindole (DAPI) (Biozol Diagnostica Vertrieb GmbH, Eching, 
Germany), the results were evaluated using an Olympus IX71 microscope.  
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3.3. Statistics 
 
Statistical significance was analyzed using GraphPad Prism 5
 
software (GraphPad Software, 
San Diego, CA, USA). Significance
 
was assessed with a Mann-Whitney rank sum or 
Student‟s t test. A P value less than 0.05 was considered statistically significant. 
 
4. RESULTS 
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4.1. In vitro studies 
 
4.1.1. Phenotypic characterization of CD271
+
 bone marrow mononuclear cells 
 
To determine the phenotype of CD271
+
 MSC progenitor cells, BM-MNC
 
were stained with 
monoclonal antibodies against typical MSC
 
antigens. Gating on all CD271
+
 BM-MNC 
(Figure 3A), we found that most of these cells (60–95%) expressed CD29, HLA-A, HLA-B, 
HLA-C, HLA-DR, and CD166. A considerable
 
proportion of cells (20–30%) expressed 
CD105, CD15, CD13,
 
SSEA-1, CD184, CD56, CD34, and CD133. However, only a small
 
proportion of cells (10–20%) expressed CD146, CD73, CD90, and early stage-specific 
embryonic antigen-4 (SSEA-4) (Figure 3B). 
 
 
 
Figure 3. Phenotypic characterization of CD271
+
 bone marrow mononuclear cells. 
(A) A representative dot plot of CD271
+
 bone marrow mononuclear cells. (B) Cell surface 
profile of CD271
+
 bone marrow mononuclear cells after density gradient separation. The 
positivity for analyzed antigens was determined by gating on all CD271
+
 BM-MNC.  
 
As assessed by flow cytometry,
 
the frequency of CD271
+
 cells in the BM-MNC
 
samples used 
in this study was 0.6±0.1% (range, 0.2% to 1.2%; median
 
0.5%).The frequency of CD271
+
 
BM-MNCs varied from donor to donor and no correlation between the donor age and 
frequency of this cell fraction in the bone marrow samples has been observed (Figure 4).  
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Figure 4. Frequency of CD271
+
 bone marrow mononuclear cells.  
Bone marrow mononuclear cells of healthy donors (n=10) isolated by ficoll-gradient were 
labeled with the phycoerythrin (PE)-conjugated mouse anti-human CD271 antibody. The 
percentage of CD271
+
 BM-MNCs was determined by means of flow cytometry. 
 
4.1.2. Clonogenic and proliferative potential of mesenchymal stromal cells derived from  
CD271
+
 bone marrow mononuclear cells 
 
As mentioned above the mean frequency of CD271
+
 BM-MNCs in our sample from 10 
donors was 0.6%. The purity of positively selected CD271
+
 BM-MNC by immunomagnetic 
selection was 92.3±5.9% (range 80% to 98%) (Figure 5) with a recovery of 75±20%. These 
highly purified cells were used for generation of CFU-Fs as an assay for enumeration of 
progenitor cells of MSCs (Figure 6) as well as for generation of bulk quantities of CD271-
MSC that have been used throughout the study. In all experiments performed in this study 
PA-MSCs were used as a control. 
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Figure 5. Positive selection of CD271
+
 bone marrow mononuclear cells. 
(A) A representative dot plot of CD271
+
 bone marrow mononuclear cells before enrichment. 
(B) A representative dot plot of positively selected CD271
+ 
BM-MNCs. BM-MNCs (n=10) 
were incubated with monoclonal anti-human CD271 antibody conjugated to allophycocyanin 
(APC) (clone ME20.4) and thereafter with anti-APC magnetic beads. The enrichment of 
CD271
+
 cells was performed by a MACS separator. Highly purified CD271
+
 BM-MNCs were 
collected and used for further analysis. 
 
 
 
Figure 6. Generation of colony forming unit-fibroblast (CFU-F). 
(A) 2.5x10
4
 of purified CD271
+
 BM-MNCs were plated into tissue culture flasks. After 13 
days in culture, staining with Giemsa’s azur eosin methylene blue solution showed the 
presence of spot-like formations in the flasks. Enumeration of these formations by microscopy 
demonstrated that they consist of spindle-shaped cells: MSCs. (B) Generation of CFU-Fs with 
unseparated BM-MNCs (2.5x10
5
 cells/flask). Magnification for both microscopic pictures: 
40x. 
  
49 
To estimate the number of progenitor cells for MSCs by means of CFU-F assay, highly 
purified CD271
+
 BM-MNCs (1x10
5
, 0.5x10
5
, and 0.25x10
5
) were cultured in both FBS-
containing culture medium (Figure 7A) as well as in the animal serum-free medium (platelet 
lysate) (Figure 7B) and colony-forming efficiency (CFE) was calculated. 
An average of 0.2 ± 0.04 CFU-F/10
2 
cells (1 progenitor cell for MSCs in 500 enriched 
CD271
+
 BM-MNCs) was observed in the CD271
+
 fraction cultured with FBS-containing 
medium compared to CD271
+
 fraction cultured with platelet lysate-containing medium 
(serum-free) whereby the CFE was 0.15 ± 0.024 CFU-F/10
2
 cells (0.75 progenitors for MSC 
in 500 enriched CD271
+
 BM-MNCs). However, compared to the unseparated BM-MNCs 
cultured in FBS-containing medium this frequency represented a 26-fold enrichment of CFU-
Fs (MSC-progenitors) within the CD271
+
 cell fraction (P<0.0001) (Figure 7A). In addition, 
the number of CFU-Fs was also significantly enriched (20.3-fold) in the CD271
+
 BM-MNC 
fraction cultured in the medium supplemented with platelet lysate compared to unseparated 
BM-MNCs (P<0.0001) (Figure 7B). No colonies were formed by CD271
–
 cells plated
 
at a 
100-fold higher density than enriched CD271
+
 BM-MNCs (data not shown). 
 
 
 
 
Figure 7. Number of progenitor cells for MSCs (CFU-Fs) in culture medium supplemented 
with fetal bovine serum or platelet lysates. 
Enriched CD271
+
 BM-MNCs as well as unseparated BM-MNCs were cultured for 13 days in 
the DMEM culture medium supplemented with 10% fetal bovine serum (A) and in DMEM 
supplemented with 5% platelet lysate (B). On day 13, the number of fibroblast-like colonies 
was scored and the frequency of CFU-F per 1x10
6
 of CD271
+
 BM-MNCs and unseparated 
BM-MNC was calculated. The results are presented as mean values ± SEM (n=10). 
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Analysis of the cellularity of CFU-Fs at day 13 revealed that although the number of colonies 
derived from CD271
+
 BM-MNCs cultured in FBS-containing medium was 26-fold higher, 
they contained only 7-fold more cells than CFU-Fs generated by BM-MNCs (P<0.03). The 
cellularity of all CFU-Fs generated from CD271
+
 BM-MNCs varied from 7.5 x 10
5
 to 16 x 
10
6
 (Figure 8). In addition, the cellularity of CFU-Fs at day 13 demonstrated that although the 
number of colonies derived from CD271
+
 BM-MNCs cultured in the medium supplemented 
with platelet lysate was 20.3-fold higher than the number of CFU-Fs formed by BM-MNCs, 
they contained only 8-fold more cells (P<0.005). The cellularity of all CFU-Fs generated from 
CD271
+
 BM-MNCs varied from 5.4 x 10
4
 to 2.1 x 10
6
 (Figure 8). 
 
 
Figure 8. Cellularity of CFU-Fs generated by CD271
+
 BM-MNCs and unseparated BM-
MNCs. Hundred-thousand of enriched CD271
+
 BM-MNCs were cultured either in DMEM 
supplemented with 10% FBS or DMEM supplemented with 5% platelet lysate (PL). In 
addition, 1x 10
6
 BM-MNCs were cultured in either of these media. On day 13 the number of 
CFU-Fs was estimated by microscopy. Thereafter, the cells were detached by trypsin and the 
number of viable MSCs was determined by trypan blue staining. Number of MSCs were 
calculated to 1x10
6
 CD271
+
 BM-MNCs or unseparated BM-MNCs. Results are presented as 
mean values ± SEM (n=10). 
 
Comparative analysis of the number of CFU-Fs and the age of bone marrow donors, 
demonstrated no correlation between these two parameters neither for CFU-Fs generated by 
enriched CD271
+
 BM-MNCs (Figure 9A) nor for CFU-Fs generated by unseparated BM-
MNCs (Figure 9B). Neither was found a correlation between the frequency of CD271
+
 BM-
MNCs and age of the donors, nor between these two parameters and the potential to generate 
CFU-Fs. For instance, one 22-year old donor whose bone marrow expressed 1% CD271 
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antigen generated only 602 CFU-Fs. The other donor of the same age (22 years) whose bone 
marrow expressed only 0.2% of CD271
+
 cells generated 4.6- fold more colonies (2.800 CFU-
F). 
 
 
 
Figure 9. CFU-F potential and the age of donors. (A) Potential of enriched CD271
+
 BM-
MNCs from individual donors of different ages to give rise to CFU-Fs. (B) Potential of 
unseparated BM-MNCs from individual donors of different ages to generate CFU-Fs. 
 
In order to evaluate the potential of the enriched CD271
+
 BM-MNCs to give rise to 
mesenchymal stromal cells (CD271-MSCs) and their consequent proliferation, these cells 
were cultured in DMEM-low glucose culture medium supplemented either with 10% MSC-
qualified FBS or 5% platelet lysate (animal serum-free medium). In parallel, potential of 
unseparated BM-MNCs to give rise to mesenchymal stromal cells (PA-MSCs) and proliferate 
under the same culture conditions was used as a control. Estimation of population doublings 
(PD) over a period of 30
 
days revealed no significant differences in the proliferative
 
potential 
of CD271-MSC compared to PA-MSC. Both types of MSCs demonstrated very similar 
growth kinetics by day 30 in the culture medium supplemented either with FBS (CD271-
MSCs: 19.5 ± 1.3 PD; PA-MSCs: 19.3 ± 1.0 PD) (Figure 10A) or with platelet lysate 
(CD271-MSCs: 17.0 ± 1.2; PA-MSCs: 14.7 ± 2.6) (Figure 10B). 
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Figure 10. Growth kinetics of CD271-MSCs and PA-MSCs. 
(A) Growth kinetics of MSCs in culture medium DMEM supplemented with 10% FBS (n=8). 
To estimate the number of population doublings, cultured MSCs were trypsinized in weekly 
intervals and the viable number of MSCs was determined by trypan blue staining. (B) The 
number of population doublings in both types of MSCs cultured in DMEM supplemented with 
5% platelet lysates (n=3). Results are presented as mean values ± SEM. 
 
Determination of doubling time demonstrated that CD271-MSCs need a shorter time to 
duplicate themselves when cultured in serum-free medium (Figure 11A). In addition, the 
doubling time was prolongated by the time in culture, e.g. while at passage 1 and 2 the 
doubling time of these MSCs was in average 1.6 days (38.4 hours), by passage 4 the doubling 
time became significantly longer (2.3 days or 55.2 hours). PA-MSCs at passage 4 cultured 
under the same conditions needed in average 2.96 days (71 hours) to duplicate themselves. 
However, the differences were not statistically significant, because of large variations 
between donors. These doubling times were comparable to the doubling times of CD271-
MSCs and PA-MSCs cultured in presence of animal serum (10% FBS) (Figure 11B), 
suggesting that platelet lysate has equal stimulatory properties for proliferation of both types 
of MSCs as FBS. Therefore, FBS can be freely replaced by platelet lysate in order to generate 
bulk quantities of animal serum-free MSCs for clinical application. 
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Figure 11. Doubling time of CD271-MSCs and PA-MSCs in serum-containing and serum-
free media. (A) Doubling time of both types of MSCs in serum-free medium (DMEM 
supplemented with 5% platelet lysate) (n=3) and (B) serum-containing medium (DMEM 
supplemented with 10% FBS) (n=8). Results are presented as mean values ± SEM. 
 
4.1.3  Phenotype and differentiation potential of the expanded mesenchymal stromal cells 
derived from CD271
+
 BM-MNCs (CD271-MSCs) 
 
Passage 4 CD271-MSC expressed typical mesenchymal cell surface
 
markers, such as CD73, 
CD90, CD105, CD146, CD44, CD29, CD166, and HLA class
 
I molecules. However, they 
were negative for the hematopoietic
 
cell markers CD14, CD45, hematopoietic stem cell 
marker CD34 as well as class II HLA-antigens (HLA-DR) (Figure 12). This phenotypic 
profile was observed in both CD271-MSCs cultured in FBS-containing medium and medium 
supplemented with platelet lysate (serum-free). In addition, mesenchymal stromal cells 
generated through plastic adherence of unselected BM-MNCs (PA-MSCs) at passage 4 
expressed the same typical MSC antigens at the same level as CD271-MSCs, either.  
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Figure 12. Characterization of adult bone marrow-derived CD271-MSCs. 
CD271-MSCs of passage 4 were labelled with fluorochrome-conjugated mouse anti-human 
antibodies against non-hematopoietic and hematopoietic antigens. After an incubation step 
and washing, the cells were analyzed for cell surface marker expression. Isotype controls are 
presented as shaded histograms and analyzed markers as open histograms. 
 
One of the important criteria that the cells should fulfil in order to be defined as mesenchymal 
stromal cells is their capacity to differentiate along three lineages: adipocytes, osteoblasts and 
chondrocytes. In order to study the differentiation potential of CD271-MSCs to adipogenic, 
osteogenic,
 
and chondrogenic lineages, MSCs of passage 4 were cultured in
 
tissue-specific 
media according to the manufacturer‟s instructions (Miltenyi Biotec GmbH). Culture of the 
expanded CD271-MSC in tissue-specific media demonstrated that these MSCs possess an 
equal potential as PA-MSCs to differentiate along adipogenic, osteogenic, and chondrogenic 
lineages
 
(Figure 13).  
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Figure 13. Differentiation potential of CD271-MSCs. 
Like PA-MSCs, CD271-MSCs differentiate into adipocytes, osteoblasts and chondrocytes. 
Accumulation of intracellular lipid vacuoles was shown by oil red-O staining after 21 days in 
culture with NH AdipoDiff medium, while osteoblast differentiation was detected by alkaline 
phosphatase activity after 10 days in NH OsteoDiff medium. Cartilage matrix deposition 
along with chondrocytes in lacunae was demonstrated by alcian blue staining after 24 days in 
NH ChondroDiff medium. Magnification for microphotographs of MSCs and osteoblasts was 
40x; the magnification for adipocytes was 200x and for chondrocytes 400x. 
 
4.1.4. Immunomodulatory potential of CD271-MSCs 
 
4.1.4.1. Potential of CD271-MSCs to inhibit the proliferative response of peripheral 
blood mononuclear cells (PB-MNCs) to mitogens 
 
To determine whether CD271-MSC may affect the proliferative
 
response of PB-MNC to 
mitogenic stimulation, both types of lethally
 
irradiated MSC were cultured with PB-MNCs at 
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a 1:1 ratio
 
(Figure 14A). Third-party CD271-MSC markedly inhibited the proliferation
 
of PB-
MNC after mitogenic stimulation with phytohemagglutinin
 
(41.3±2.9% of control, P<0.03) 
and concanavalin-A
 
(34.3±8.0% of control, P<0.0001) as specific mitogens
 
for stimulation of  
T cells and pokeweed mitogen (48.1±9.1%
 
of control, P<0.002) as a mitogenic stimulator of  
both T
 
and B cells. In contrast, they were unable to inhibit proliferation
 
of PB-MNC after 
stimulation with the superantigen staphylococcal
 
enterotoxin B (108.8±15.6% of control, 
P<0.9) like
 
PA-MSC (Figure 14B). 
 
 
 
Figure 14. The effect of CD271-MSC on proliferation of mitogen-activated lymphocytes. 
The figure shows the inhibitory effect of the CD271-MSC population (A) and PA-MSC 
population at passage 4 at ratio 1:1 (B). In each experiment, 100,000 peripheral blood 
lymphocytes were stimulated in triplicate with phytohemagglutin (PHA), concanavalin A 
(con-A), pokeweed mitogen (PWM), interleukin- 2 (IL-2) and staphylococcal enterotoxin B 
(SEB) in the presence or absence (control group) of lethally irradiated mesenchymal stromal 
cells (10
5
). The values represent the mean of the triplicate experiments ± standard error of 
mean (SEM) (n=7). Statistically significant differences between groups were assessed with a 
Student’s t test. P values of less than 0.05 were considered to be statistically significant: 
*P<0.02; **P<0.003;*** P<0.0001. 
 
4.1.4.2. Inhibition of allogeneic reaction through CD271- MSC 
 
As MSCs are often used for the treatment of graft-versus-host disease, it is preferable to 
expand these cells in serum-free media. This was the major reason to expand CD271-MSCs 
either in FBS-containing or platelet lysate-containing media and assess their allosuppresive 
effect in mixed lymphocyte reaction. CD271-MSCs expanded in FBS-containing medium 
demonstrated a significant inhibitory effect on allogeneic driven proliferation of MNCs from 
two randomly chosen unrelated donors. CD271-MSCs were most effective at the MSC:MNC 
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ratios of 1:1 (P< 0.0009) and 1:2 (P< 0.001), and to a lesser extent at the ratio 1:10 (P< 0.01) 
(Figure 15A). Interestingly, indomethacin, an inhibitor of cyclooxygenase-1 and 2 necessary 
for the biosynthesis of PGE2, was not able to significantly abrogate the inhibitory effect of 
MSCs on proliferation of MNCs at the ratios 1:2 and 1:10. However, it reduced significantly 
this effect of CD271-MSCs at the ratio MSCs:MNCs=1:1. In contrast, PA-MSCs were able to 
suppress the alloantigen-induced proliferation of MNCs only at MSC:MNC ratios 1:1 and 1:2, 
but not at 1:10 ratio (Figure 15B). 
 
 
 
Figure 15. Allosuppressive effect of CD271-MSCs cultured in serum-containing medium. 
In this figure is presented the inhibition of allogeneic reaction through CD271-MSCs (A) and 
PA-MSCs (B). MNCs of two unrelated donors were cultured for 5 days either alone (control 
group) or with lethally irradiated third-party MSCs at the MSC:MNC ratio of 1:1, 1:2 and 
1:10. To demonstrate the MSC-mediated inhibition by prostaglandin E2 (PGE2), the MSCs 
were cultured with MNCs in the presence or absence of the PGE2 inhibitor, indomethacin 
(IM, final concentration: 5 μM). Proliferation levels of MNCs were determined on day 6 by 
means of the BrdU assay. The significance of inhibition of proliferation of allogeneic cells by 
MSCs and abrogation of this effect by indomethacin was assessed with a Student’s t test. P 
values of less than 0.05 were considered to be statistically significant. The experiment was 
performed with eight unrelated MSC-MNC donor pairs. 
 
In addition, CD271-MSCs were successfully expanded in the medium supplemented with 5% 
of platelet lysate. These MSCs demonstrated a significant allosuppressive effect on allogeneic 
driven proliferation of MNCs from two randomly chosen unrelated donors. CD271-MSCs 
were most effective at the MNC: MSC ratios of 1:1 (P< 0.03) and 2:1 (P< 0.04) (Figure 16A). 
Indomethacin, as an inhibitor of cyclooxygenase-1 and 2 necessary for the biosynthesis of 
PGE2, was able to reverse the inhibitory effect of MSCs at both ratios 1:1 and 2:1. Like 
CD271-MSCs, PA-MSCs were also able to significantly suppress the alloantigen-induced 
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proliferation of MNCs only at MNC:MSC ratios 1:1 (P< 0.0001) and 2:1 (P< 0.0009) (Figure 
16B). 
 
 
 
Figure 16. Allosuppressive effect of CD271-MSCs cultured in serum-free medium.  
In this figure is presented the inhibition of allogeneic reaction through CD271-MSCs (A) and 
PA-MSCs (B) previously cultured in the medium supplemented with 5% platelet lysate 
(serum-free). MNCs of two unrelated donors were cultured for 5 days either alone (control 
group) or with lethally irradiated third-party MSC at the ratio of 1:1 and 2:1. To demonstrate 
the MSC-mediated inhibition by prostaglandin E2 (PGE2), the MSCs were cultured with 
MNCs in the presence or absence of the PGE2 inhibitor, indomethacin (IM, final 
concentration: 5 μM). Proliferation levels of MNCs were determined on day 6 by means of the 
BrdU assay. The significance of inhibition of proliferation of allogeneic cells by MSCs was 
assessed with a Student’s t test. P values of less than 0.05 were considered to be statistically 
significant. Values are presented as mean± SEM (n=3).  
 
4.1.5. Effector soluble molecules of MSC-mediated immunosuppression 
 
4.1.5.1. Prostaglandin E2 (PGE2) 
 
In the MLR as a result of the allogeneic reaction there was a baseline level of PGE2 (3.3±0.68 
ng/ml). On the other hand, CD271-MSCs alone produced also low levels of this molecule 
(5.29±0.71 ng/ml). However, contact of MSCs with the HLA-mismatched mononuclear cells 
at 1:1 and 1:2 ratio resulted in a significant increase of PGE2 production (23.8±5.04 ng/ml, 
P<0.007; and 23.14±2.93 ng/ml, P<0.0006, respectively). Remarkably, at a CD271-
MSC:MNC ratio of 1:10 there was no increase in PGE2 production (3.52±1.06 ng/ml) (Figure 
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17A). Indomethacin as a specific blocker of PGE2 synthesis inhibited its production at ratios 
1:1 and 1:2 but not at the ratio 1:10. Similar values were obtained when the PA-MSCs were 
used in MLR (Figure 17B). 
 
 
 
Figure 17. Concentration of prostaglandin E2 in the supernatants of MLR.  
Levels of PGE2 in the supernatants of MLR at different CD271-MSC:MNC (A) or PA-
MSC:MNC ratios (B). The results are shown as mean values ± SEM of 6 independent 
experiments. 
 
4.1.5.2. Soluble HLA-G (sHLA-G) and nitric oxide (NO) molecules 
 
In addition to PGE2, the levels of soluble HLA-G and nitric monoxide in the supernatants of 
MLR in presence and absence of CD271-MSC were assessed. As shown in Figure 18A, no 
significant differences were observed in the levels of sHLA-G when MNCs were incubated 
with CD271-MSCs (7.3±0.2 U/ml) or PA-MSCs (6.4±0.3 U/ml) in comparison to the MNCs 
from two unrelated donors (6.4±0.4 U/ml). Baseline levels for sHLA-G released by CD271-
MSCs were equal to the levels of this molecule released by PA-MSCs (6.3±0.7 U/ml or 
6.4±0.6 U/ml, respectively). 
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To further examine the possible role of NO in MSC-mediated immunosuppression, levels of 
this molecule in the MLR supernatants at the MNC:CD271-MSC or MNC:PA-MSC ratio of 
1:1 (Figure 18B) were assessed. No significant differences were found between the levels of 
NO in the supernatant of MLR either at MNC:CD271-MSC or MNC:PA-MSC ratio 1:1 
(25.2±3.3 µM and 24.6±3.8 µM, respectively). In addition, blockade of NO synthesis by 
means of N-nitro-L-arginine methyl ester (L-NAME) (a NO-synthase inhibitor) did not affect 
the suppressive effect of either CD271-MSCs or PA-MSCs in MLR (data not shown). 
 
 
 
Figure 18. Levels of sHLA-G and NO in the supernatants of MLR. 
On day 6 of MLR the supernatants were collected and frozen until use. After thawing the 
samples were appropriately diluted and the levels of soluble HLA-G (A) and NO (B) in the 
supernatants of MLR at MNC:CD271-MSC or MNC:PA-MSC ratio of 1:1 were estimated. 
The results are shown as mean values ± SEM of 5 independent experiments. 
 
4.1.5.3. Cytokine profile of the supernatants of MLR 
 
MSCs have been shown to exert an anti-inflammatory effect in the allogeneic reaction. 
Determination of cytokines in the supernatants of MLR in the presence of CD271-MSCs 
revealed a significant decrease of the levels of inflammatory cytokines such as IFN-gamma 
and TNF-alpha. CD271-MSCs decreased the IFN-gamma levels significantly either at 
MNC:CD271-MSCs ratio of 1:1 (76.1±24.3 pg/ml, P<0.02) or 2:1 (124.8±32.3 pg/ml, 
P<0.03) compared to MNCs alone (612.4±176.1 pg/ml). In contrast, PA-MSCs decreased 
IFN-gamma levels slightly at 1:1 and significantly at the MNC:PA-MSC ratio of 2:1 (P<0.03) 
(Figure 19A). As a consequence of alloreaction, levels of TNF-alpha were increased in the 
supernatants of MNCs in MLR (404.3±82.9 pg/ml). However, the presence of CD271-MSCs 
induced a significant decrease either at ratio MNCs:CD271-MSCs of 1:1 or 2:1 (12.9±3.1 
pg/ml, P<0.003; or 13.3±0.4 pg/ml, P<0.003, respectively) (Figure 19B). No significant 
changes were observed in the levels of Fas-ligand levels in the presence of CD271-MSCs, 
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even if CD271-MSCs induced a decrease in the levels of this ligand (Figure 19C). In contrast, 
co-culture of MNCs with CD271-MSCs resulted in a significant increase of IL-2 levels at the 
ratio 1:1 (140.6±33.9 pg/ml) and 2:1 (137±35 pg/ml) (P<0.04) compared to the levels of this 
cytokine in the supernatants of MNCs alone (29.8±4.7 pg/ml) (Figure 19D). CD271-MSCs 
produced high baseline levels of angiogenin (568.6±166.2 pg/ml) and VEGF (20385±6310 
pg/ml). In addition, co-incubation of these MSCs with allogeneic MNCs did not change levels 
of these cytokines (data not shown). Remarkably, no changes in the levels of IL-10 in the 
supernatants of MLR have been observed (data not shown). PA-MSCs, which were used as a 
control throughout the study, demonstrated approximately the same potential as CD271-
MSCs. 
 
 
Figure 19. Estimation of cytokine levels in the supernatants of MLR.  
Supernatants of MLR were collected on day 6 and were frozen until use. After thawing, they 
were appropriately diluted and used to estimate the levels of a series of cytokines e.g. IFN-
gamma (A), TNF-alpha (B), Fas-L (C) and IL-2 (D) by BD FACSArray. Results are shown as 
mean ± SEM of 4 independent experiments.  
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4.1.6. T regulatory cells (T regs) 
 
CD4
+
CD25
+
 T cells are potent regulators of alloimmune responses. In order to assess their 
role in MSC-mediating immunosuppression of allogeneic reaction the proportion of these 
cells at day 0 and 6 in mixed lymphocyte reaction was estimated. Flow cytometric analysis 
demonstrated that the percentage of T regs in the mixture of MNCs of 2 HLA-mismatched 
donors was 3±2.2% (Figure 20A) whereas proportion of naïve T regs 
(CD4
+
CD25
high
CD45RA
+
) was 34.5± 6.4%. By the time in culture (day 6) number of T regs 
as a consequence of allogeneic reaction significantly increased from 3±2.2% to 21.6±5.3% 
(P<0.02) (Figure 20A). In contrast, in presence of CD271-MSC the number of T regs at day 6 
significantly decreased to 8.5±1.9% compared to the percentage of these cells in the absence 
of MSCs (21.6±5.3%) (P<0.05) (Figure 20B). Remarkably, despite the decrease of number of 
T regs in the presence of CD271-MSCs the percentage of naïve T regs 
(CD4
+
CD25
high
CD45RA
+
) increased significantly from 37.1± 5.9% (day 6, MNCs without 
MSCs) to 66.5± 4.7% (P<0.02) (Fig. 20C). All these cells (98±1.4%) expressed CD62L, an 
important T-cell homing receptor. PA-MSCs showed a similar effect on T regs and their 
subpopulations. 
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Figure 20. The effect of CD271-MSCs on T-regulatory cells in MLR. 
(A) A representative dot plot of T-regulatory cells on day 0 of MLR and day 6 (in absence or 
presence of CD271-MSCs). CD271-MSCs like PA-MSCs decreased the overall number of 
CD4
+
CD25
high
 T-regs on day 6 of MLR (B). In contrast, they increased significantly the 
percentage of naïve T-regulatory cells (CD4
+
CD25
high
CD45RA
+
CD62L
+
) within population 
of T-regs (C). Results are presented as mean ± SEM of 6 independent experiments. 
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4.2. In vivo studies 
 
4.2.1. Multilineage engraftment of hematopoietic CD133
+
 stem cells after co- 
transplantation with CD271-mesenchymal stromal cells 
 
Several lines of evidence suggest that PA-MSC induce improved
 
hematopoietic engraftment. 
However, thus far there is no evidence
 
regarding the capacity of CD271-MSC on engraftment
 
of hematopoietic stem cells or their multilineage differentiation potential
 
in vivo. Flow 
cytometric analysis using an anti-human CD45 antibody
 
demonstrated significantly improved 
engraftment of hematopoietic
 
CD133
+
 cells in the bone marrow of NOD/SCID mice co-
transplanted
 
with either CD271- MSC (2.9±0.9%, P<0.01) or PA-MSC
 
(2.0±0.5%, P<0.02) at 
a ratio of 1:1 in comparison
 
to that in a control group of mice transplanted with CD133
+ 
cells 
only (0.3±0.02%) (Figure 21).  
 
 
 
 
Figure 21. Hematopoietic engraftment of human CD133
+
 cells in bone marrow of 
NOD/SCID IL-2Rγnull mice. Experimental design of the in vivo studies: Five groups of 
NOD/SCID IL-2Rγnull mice (5 mice each) were sublethaly irradiated and on the next day 
transplanted with 1x10
5 
human CD133
+
 cells only (control group), 1x10
5
 CD133
+
 cells and 
1x10
5
 human GFP-transduced CD271-MSC (ratio 1:1) and the other group with 1x10
5
 
CD133
+
 cells and 7x10
5
 human GFP-transfected CD271-MSC (ratio 1:8). At the same ratios 
1x10
5
 CD133
+
 cells were transplanted with GFP-transduced PA-MSC. The overall human 
cell engraftment in the bone marrow (as measured by anti-human CD45 immunostaining) 14 
weeks post-transplantation is shown in the right panel. The top right panel shows the graph 
for co-transplantation of CD133
+
 cells with CD271-MSC; the bottom right panel shows co-
transplantation of CD133
+
 cells with PA-MSC. 
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Both types of MSC
 
at this ratio showed similar effects; the number of myeloid
 
(CD33
+
) cells 
increased between 2- and 3-fold, whereas the number
 
of megakaryocytes (CD41a
+
) remained 
at levels comparable to
 
those present in the control group. It is noteworthy that, at
 
this ratio, 
both types of co-transplanted MSC increased the
 
number of cells with a B-cell phenotype 
(CD19
+
) about 8- to
 
9-fold (15.4±8.1% when CD271-MSC were co-transplanted
 
and 
13.3±4.2% when PA-MSC were co-transplanted) compared
 
with the number in the control 
group (1.7±0.7%). Furthermore,
 
neither type of MSC at this ratio showed an effect on the 
development
 
of cells with a T-cell (CD3
+
), NK-cell (CD56
+
), or NKT-cell
 
(CD3
+
CD56
+
) 
phenotype from engrafted CD133
+
 cells (data not shown). 
 
 
 
Figure 22. Multilineage differentiation of CD133
+
 hematopoietic stem cells after co-
transplantation with mesenchymal stromal cells. (A) A representative dot plot of the group 
transplanted with 1x10
5
 mobilized peripheral blood CD133
+
 cells only, the group co-
transplantated with PA-MSC at the ratio 1:8 (B) and the group co-transplanted with CD271-
MSC at the ratio 1:8 (C). (D) Multilineage differentiation of CD133
+
 without or with co-
transplantation of CD271-MSC or PA-MSC, respectively. The percentage of positive cells for 
each lineage marker was determined by gating on human CD45
+
 cells as shown in panels A, 
B and C. Differences in the engraftment level of each cell population between the groups were 
tested by Student’s t-test. A P value of less than 0.05 was considered to be statistically 
significant. (E) Representative flow cytometric data on the engraftment of human T, NK and 
NKT cells in the group transplanted with 10
5
 CD133
+
 cells and 7x10
5
 CD271-MSC (1:8 
ratio). 
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In contrast,
 
co-transplantation of CD133
+
 cells with PA-MSC at a ratio of
 
1:8 (Figure 22B) 
induced greater overall engraftment of the hematopoietic
 
cells in the bone marrow compared 
to CD271-MSC (Figure 22C) and
 
to the control group (Figure 22A). Both types of MSC 
transplanted
 
at this ratio doubled the number of myeloid cells (CD33
+
) and
 
megakaryocytes 
(CD41a
+
) in comparison to the group transplanted
 
with CD133
+
 cells alone. However, co-
transplantation of CD133
+ 
hematopoietic cells with CD271-MSC at a ratio of 1:8 induced
 
their multilineage differentiation by giving rise to cells with
 
a lymphoid lineage phenotype.  
The numbers of cells with a T-cell
 
and B-cell phenotype were roughly 7-fold (P<0.01) and 4-
fold
 
higher than those in the control group (Figure 22D). The number
 
of NK cells decreased 
significantly (Figure 22E) to the normal
 
levels compared to the control group, thereby 
demonstrating a declined expansion (P<0.0005) and suggesting that CD271-MSC may
 
control 
the in vivo proliferation of these cells. In contrast,
 
PA-MSC failed to give rise to the lymphoid 
lineage to the same
 
extent as CD271-MSC, indicating a major qualitative difference
 
between 
these two MSC populations. 
 
4.2.2. Distribution of human cells in the organs of co-transplanted NOD/SCID mice 
 
Real-time polymerase chain reaction analysis of organs from
 
the mice co-transplanted with 
CD133
+
 hematopoietic stem cells
 
and CD271-MSC or PA-MSC demonstrated a detectable 
presence of
 
human DNA in all organs (Figure 23A–C). When both types of MSC were 
transplanted with hematopoietic stem cells at a
 
ratio of 1:1, most of the human DNA was 
detected in the brain
 
and, to a lesser extent, in the lungs, liver, heart, and skeletal
 
muscle. 
Approximately 2% of the human DNA in immunodeficient
 
mice was detected in the brain. In 
contrast to this finding,
 
co-transplantation of CD133
+
 hematopoietic stem cells with MSCs
 
at a 
ratio of 1:8 was associated with an increase in human DNA
 
in the lungs, suggesting the 
possible entrapment of human cells
 
in this organ. When hematopoietic stem cells were co-
transplanted
 
with CD271-MSC or PA-MSC at a ratio of 1:8, the amount of human
 
DNA in the 
lungs represented about 0.7±0.16% or 1.4±0.25%,
 
respectively. In addition to the lungs, the 
second organ in
 
which human DNA was detected at significant quantities was the
 
liver; very 
low amounts of human DNA were detected in the brain,
 
heart, and skeletal muscle (Figure 
23C). In contrast, real-time
 
polymerase chain reaction analysis of mouse organs transplanted
 
with different doses of CD271-MSC or PA-MSC separately revealed
 
consistently higher 
amounts of human DNA in the lungs, and very
 
low levels in the liver, heart, and skeletal 
muscle. No human
 
DNA was detected in the brain of the mice indicating a typical migration 
pattern of MSC
 
with lung entrapment of these cells (data not shown). 
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Figure 23. Distribution of human cells in the tissues of NOD/SCID mice 14 weeks after 
transplantation. (A) Real-time PCR amplification of human albumin gene in tissue samples of 
mice co-transplanted with human CD133
+
 cells and CD271-MSC at a ratio of 1:1. (B) Real-
time PCR amplification of human albumin gene in tissue samples of mice co-transplanted 
with human CD133
+
 cells and CD271-MSC at a ratio 1:8. Standard curve achieved from 
serial dilutions of human DNA in mouse DNA (10
–1
 to 10
–4
) is depicted with dashed lines. (C) 
Organ distribution of human cells in mouse tissues. Fourteen weeks after transplantation 
genomic DNA was extracted and the presence of human-specific DNA in the organs of 
transplanted mice was confirmed by real-time PCR for human albumin gene. The values 
represent calculated mean percentages of human DNA ± SD of four measurements. 
Significant differences were observed in the brain of groups co-transplanted with HSC and 
MSC at the 1:1 ratio as compared with the content of human DNA in the brain of groups co-
transplanted with HSC and MSC at a 1:8 ratio (*P<0.04 when HSC were co-transplanted 
with CD271-MSC and *P<0.01 when HSC were co-transplanted with PA-MSC). In contrast, 
when HSC were co-transplanted with MSC at a 1:8 ratio a significantly higher amount of 
human DNA was observed in the lungs as compared to the content of human DNA in the same 
organ of mice co-transplanted with HSC and MSC at a 1:1 ratio (*P<0.01 when HSC were 
co-transplanted with CD271-MSC and *P<0.04 when HSC were co-transplanted with PA-
MSC) (D) and (E) A representative immunostaining of GFP-transduced CD271-MSC in the 
tissue sections with phycoerythrin (PE)-conjugated mouse anti-human HLA-class I and Alexa 
488-conjugated anti-GFP antibody. Localization of MSC-derived cells in the lungs (D) of 
mice co-transplanted with 7x10
5
 CD271-MSC and 10
5
 CD133
+
 HSC and brain (E) when 
CD271-MSC were co-transplanted with CD133
+
 HSC at a ratio of 1:1 (magnification 600x). 
 
 
5. DISCUSSION 
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5.1. The need for novel markers for prospective isolation of progenitor cells 
for MSCs  
 
Most of the researchers agree that one of the drawbacks of generating
 
MSC through plastic 
adherence is the unknown MSC progenitor
 
cell and the derivation of a very heterogeneous 
cell population
 
with regard to proliferative and differentiation potentials.
 
Since the origin of 
MSC still remains elusive, there is an increasing
 
need for novel markers and methods of 
detection, enumeration,
 
and isolation of MSC progenitor cells from the bone marrow and
 
other tissues as a prerequisite for establishing stringent protocols
 
for the clinical-scale 
generation of MSC without any hematopoietic
 
contamination (17;93;99;100). 
 
5.2. Clonogenic, proliferative and differentiation potential of CD271-MSCs  
 
5.2.1. Clonogenic potential 
 
The frequency of CD271
+
 cells in our sample as assessed by flow cytometry was 0.6±0.1% 
(range, 0.2% to 1.2%; median
 
0.5%), demonstrating similar values as described by Poloni et 
al. (102). However, it was lower than the frequency of CD271
+
 cells reported by Quirici et al. 
(17). The frequency of CD271
+
 BM-MNCs in our study varied from donor to donor and no 
correlation between this parameter and donor age has been observed which is in agreement 
with the results of Jones et al. (108). In addition, the number of colonies generated with the 
enriched CD271
+
 BM-MNCs in our study (2043 colonies, range 480-4540) was similar to the 
findings of Qurici et al. (17) who described an average of 2700 colonies per 1x10
6
 of 
positively selected CD271
+
 BM-MNCs (range 200-8700) and Poloni et al. (102) (1760±1130 
CFU-Fs). On the other hand, Jarocha et al. (104) obtained a three-fold lesser number of CFU-
Fs with the enriched CD271
+
 BM-MNCs compared to our data. Also, we did not observe a 
correlation between the number of CFU-Fs generated by positively selected CD271
+
BM-
MNCs and the percentage of CD271
+ 
BM-MNCs of the same donor. Using flow cytometry, 
we also found that CFU-Fs generated with highly enriched CD271
+
 BM-MNCs contained a 
very low contamination with hematopoietic cells (<1%) compared to the CFU-Cs generated 
from unseparated BM-MNCs which contained in average 13% hematopoietic cells (range: 3 
to 21.6%) (data not shown). Therefore, the enrichment of CD271
+
 cells enables a positive 
selection of MSC-progenitors from bone marrow and consequently prevents contamination of 
these progenitors with undesired hematopoietic cells. In contrast, the number of CFU-Fs 
generated from 1 x10
6
 of unseparated BM-MNCs differed largely between different groups 
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working with MSCs, starting from 2.5 (104), 13.6 (10) and increasing to 26-30 colonies 
(60;102;177), 44 colonies (17) or 80 colonies (108). The average number of CFU-Fs 
generated from 1 x 10
6
 unseparated BM-MNCs in our study was 77 colonies (range 12- 154), 
which was similar to the findings of Jones et al. (108).  
These differences may be explained by different culture conditions used by each group e.g. 
Quirici et al. (17) used 20% FBS to generate CFU-Fs and scored their number on day 9 as did 
Jarocha et al. (104). Another important point is that most of the groups use ficoll gradient 
1.077 g/cm
3
 to isolate BM-MNCs from bone marrow samples, which usually results in 
contamination of mononuclear cell fraction with a large number of granulocytes. We observed 
the same phenomenon in 2 out of 10 bone marrow samples in which this contamination 
diminished the number of colonies generated from unseparated BM-MNCs. Use of the ficoll 
gradient with a lower density 1.073 g/cm
3
 resulted in a 3-4 fold higher number of CFU-Fs, 
that was also demonstrated by another group (178). Several lines of evidence showed that 
there is negative correlation between the number of CFU-Fs and the age of bone marrow 
donors (60;61). In this study, we did not observe such a negative correlation most probably 
due to the small difference in the age of bone marrow donors (20-40 years old). 
 
5.2.2. Proliferative potential 
 
Several reports demonstrated that MSCs generated from CD271
+
 BM-MNCs possess a 
significantly higher proliferative potential than the MSCs derived from unseparated BM-
MNCs. Quirici et al. (17) found a 100-fold higher proliferation rate of CD271-MSCs 
compared to the PA-MSCs by using a medium supplemented with 20% FBS and bFGF. In 
this study, we used culture medium supplemented with 10% FBS only and that may be the 
reason that we were not able to observe any difference in the growth rate of both MSC-
populations. Consequently, estimation of population doublings (PD) over a period of 30 days 
in culture revealed a similar growth kinetics of both types of MSCs cultured either with FBS 
(CD271-MSCs: 19.5 ± 1.3 PD; PA-MSCs: 19.3 ± 1.0 PD) or with platelet lysate (CD271-
MSCs: 17.0 ± 1.2; PA-MSCs: 14.7 ± 2.6). Determination of doubling time demonstrated that 
CD271-MSCs need a shorter time to duplicate themselves when cultured in serum-free 
medium. In addition, the doubling time was prolongated by the time in culture, e.g. while at 
passage 1 and 2 the doubling time of these MSCs was in average 1.6 days (38.4 hours), by 
passage 4 the doubling time became significantly longer (2.3 days or 55.2 hours). PA-MSCs 
at passage 4 cultured under the same conditions needed in average 2.96 days (71 hours) to 
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duplicate themselves. However, the differences were not statistically significant and the 
doubling times were comparable to the doubling times of CD271-MSCs and PA-MSCs 
cultured in presence of animal serum (10% FBS), suggesting that platelet lysate has equal 
stimulatory properties for proliferation of both types of MSCs as FBS. Our data therefore 
suggest that platelet lysate can be used as effectively as FBS in generating bulk quantities of 
MSCs under serum-free conditions for a clinical application. 
Jones et al. (108) demonstrated an inverse correlation between the age of bone marrow donors 
(10-85 years) and the number of population doublings. In our sample we did not observe such 
a correlation most probably because of small differences in the age of bone marrow donors 
(20-40 years old donors). However, we observed large variations in proliferative potential of 
MSCs in the first passage between donors of bone marrow in agreement with the data 
reported by Phinney et al. (67). 
 
5.2.3. Differentiation potential 
 
Most of the authors agree that the differentiation potential of MSCs may be dependent on the 
age of the donor (66;69). Based on several investigations, the osteogenic differentiation of 
MSCs declined progressively with age (60;70;71). Evaluation of the levels of specific ALP 
activity showed that the osteogenic potential of MSCs declined progressively in donors older 
than 40 years, compared to “young” MSCs (donors 7-18 years old) and “adult” MSCs (18 -40 
years old), whereas chondrogenic differentiation also declined in „„aged‟‟ MSCs but this did 
not reach significance. In addition, adipogenic differentiation did not change significantly 
with age (60). In contrast, other authors did not observe any differences (64). On the other 
hand it has been reported that adipogenic differentiation of MSCs did not change significantly 
with age (60), in contrast to Moerman et al. (70) who found that aging activates adipogenic 
differentiation. There are also reports which demonstrated changes in dhe the differentiation 
potential of MSCs in the same donor depending on the time of donation (67). In our study we 
observed no correlation between differentiation potential of CD271-MSCs and the age of 
donors. The reason for that may be the pretty homogeneous age of donors (20-40 years old). 
However, differentiation potential of CD271-MSCs was donor-dependent i.e. CD271-MSCs 
of some donors differentiated better than the CD271-MSCs of the other donors. In addition, 
we did not observe any differences in the differentiation potential between CD271-MSCs and 
PA-MSCs from the same donor. 
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5.3. The immunosuppressive properties of CD271-MSCs 
 
Mesenchymal stromal cells have been shown to exert a pleiotropic immunosuppressive effect. 
There are, however, no data so far on whether CD271-MSC share
 
at least the same in vitro 
and in vivo immunosuppressive and
 
engraftment-promoting properties with PA-MSC 
(74;159;163;179;180). Our
 
in vitro data demonstrated that CD271-MSC strongly inhibited
 
the 
mitogenic-induced proliferation of PB-MNC after stimulation
 
with concanavalin-A 
(65.7±8.2% inhibition), phytohemagglutinin
 
(58.7%±2.9%), or pokeweed mitogen 
(51.9±9.1%) and are in agreement with the findings of Aggarwal et al. (74). On the other 
hand, CD271-MSCs as well as PA-MSCs in our experiments effectively suppressed the 
allogeneic reaction ranging from 40-80% of the maximal proliferation. Le Blanc et al.(72) 
demonstrated this immunosuppressive effect by PA-MSCs. 
In the present study we also attempted to identify possible molecular mechanisms underlying 
the immunosuppressive effect of CD271-MSC on the allogeneic reaction in vitro. In contrast 
to Krampera et al. (181) who demonstrated that MSC- T cell contact is indispensable for their 
immunosuppressive effect, a number of studies showed that the suppression is variably 
sustained in transwell experiments, suggesting that a series of soluble factors is involved.  
Several reports showed that PGE2 is one of the most important molecules which mediate the 
immunossuppressive effect of PA-MSCs (74;182;183). Aggarwal and Pittenger (74) have 
shown that human MSCs can secrete PGE2 in quantities that may be sufficient to be involved 
in MSC-mediated immunomodulation. Yanez et al. (182) claimed that PGE2 has a major role 
in the inhibitory effects of MSCs on the proliferative response of T lymphocytes to mitogenic 
or allogeneic stimulation. In contrast to these data, Rasmusson et al. (75) concluded that 
addition of indomethacin, an inhibitor of prostaglandin synthesis, restored part of the 
inhibition by MSCs in PHA cultures, but did not affect MSC-induced inhibition of allogenic 
proliferation in MLR. In addition, Tse et al. (76) also reported low levels of PGE2 secretion 
by MSCs, but they did not see significant reversal in T cell proliferation when using PGE2 
synthesis inhibitors.  
In our study, we asked therefore whether PGE2 is involved in the suppression of allogeneic 
reaction in vitro by CD271-MSCs in different MSC:MNC ratios. Consistent with the data of 
Aggarwal and Pittenger (74) and Yanez et al. (182) we found a significant increase of PGE2 
concentration when CD271-MSCs were co-incubated with MNCs at the ratio 1:1 or 1:2 
(about 4.5-fold) compared to baseline levels of PGE2 produced by CD271-MSCs. This 
correlated very well with the inhibitory effect of CD271-MSCs on allogeneic reaction in 
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MLR at these ratios. Indomethacin, an inhibitor of cyclooxygenase-1 and -2 necessary for the 
biosynthesis of PGE2, mitigated the overall MSC suppressive effects only when CD271-
MSCs were co-incubated with MNCs at the ratio 1:1. However, this effect was not observed 
when CD271-MSCs were co-incubated with MNCs at ratio 1:2, suggesting that although 
present at high levels in the culture, PGE2 does not play an exclusive major role in the 
inhibitory effects of MSCs when allogeneic MNCs are in excess. In contrast, PGE2 
concentration remained at baseline levels when CD271-MSCs were co-incubated with MNCs 
at the ratio 1:10. Remarkably, only CD271-MSCs were able to elicit a potent allosuppression 
at this ratio. To our knowledge, this is the first time to demonstrate that CD271-MSC are 
more effective in suppression of alloantigen-induced response at lower concentrations and 
that they use PGE2 as a mediator of this effect only when they are present in equal numbers 
with MNCs (1:1 ratio) but not when the MNCs are in excess (1:2 and 1:10 ratio). 
Recently, Selmani et al. (184;185) reported that the nonclassic human leukocyte antigen 
(HLA) class I molecule HLA-G is responsible for the immunomodulatory properties of 
MSCs. They showed that MSCs secrete the soluble isoform HLA-G5 and that such secretion 
is interleukin-10-dependent. Moreover, cell contact between MSCs and allostimulated T cells 
is required to obtain a full HLA-G5 secretion and, as consequence, a full immunomodulation 
from MSCs. In addition, Sato et al. (174) found in mice that Stat5 phosphorylation in T cells 
is suppressed in the presence of MSCs and that nitric oxide (NO) is involved in the 
suppression of Stat5 phosphorylation and T-cell proliferation. In the present study we 
assessed whether PGE2 acted alone or in concert with soluble HLA-G isoforms (HLA-G1 and 
HLA-G5) and nitric oxide in order to suppress the allogeneic reaction in MLR. In co-culture 
conditions at all CD271-MSC:MNC ratios used in our experiments we did not find any 
significant increase of soluble HLA-G molecules. Their levels (3.0±0.08 ng/ml) did not 
significantly differ from baseline levels (2.6±0.3 ng/ml) produced by MNCs only. This 
disagreement with the results reported by Selmani et al. (185) may be explained by the fact 
that the authors stimulated secretion of sHLA-G by exogeneous addition of IL-10. Low levels 
of this cytokine as measured in the MLR supernatants of our samples (data not shown) were 
apparently not sufficient to initiate secretion of HLA-G molecules by CD271-MSC. To the 
question of whether nitric oxide is produced by CD271-MSC in co-culture with allogeneic 
MNCs, we detected comparable amounts of this molecule which were not different from 
amounts produced by MNCs only. Moreover, L-NAME (a specific NO-synthase inhibitor) 
was not able to restore MNC proliferation in MLR (data not shown), indicating that this 
molecule does not contribute to the MSC-mediated immunosuppression in humans, either. 
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The immune behavior of MSCs can be influenced not only by neighboring cells but also 
environmental factors like systemic or local inflammation as in case of graft versus host 
disease (GVHD). An emerging body of evidence indicates that pro-inflammatory cytokines 
IFN-gamma and TNF-alpha are key mediating inflammatory events during several injury and 
pathological situations. IFN-gamma has been reported to enhance the immune-suppressive 
behavior of MSCs by upregulation of inhibitory molecule B7-H1 (186) or by IDO production 
as a key player in immuno-suppression of T cells (167). On the other hand, experiments in 
vitro showed that the addition of TNF-alpha to MLR (187) was sufficient to reverse the 
immunosuppressive effect of MSCs on T cell proliferation, and this observation was 
associated with an increase in interleukin-6 secretion. In our experimental MLR setting we 
observed high levels of IFN-gamma and TNF-alpha as a result of allogeneic reaction between 
two HLA-mismatched donors of MNCs. CD271-MSCs themselves produced low levels of 
these two cytokines. However, CD271-MSCs in co-culture with allogeneic MNCs, were able 
to significantly decrease concentration of IFN-gamma (about 80%) and TNF-alpha (about 
90%) at both 1:1 and 1:2 ratio, indicating their strong anti-inflammatory effect. Aggarwal et 
al. (74) reported a decrease of IFN-gamma for about 50% in the presence of PA-MSCs. In 
addition, CD271-MSCs revealed also a considerable anti-apoptotic effect in the MLR by 
reducing levels of Fas ligand, as a member of tumor necrosis factor family. A similar effect 
has been observed for PA-MSCs, either. Rasmusson et al. (75) have found that MSCs 
increased the production of IL-2 and IL-2R in MLRs, on both the transcriptional and 
translational level. Furthermore, they also demonstrated that MSCs do not produce IL-2, IL-
2R, or IL-10 as culture supernatants were negative. Remarkably, our data show that the 
allogeneic reaction by itself does not result in an increase of IL-2 production. However, co-
culture with either CD271-MSCs or PA-MNCs induced a significant elevation of IL-2 levels 
in the MLR-supernatants. Despite this increase, MSCs were able to significantly suppress 
proliferation of MNCs, indicating that MSCs inhibit T cells even when more IL-2 is secreted, 
probably by activating a point of inhibition downstream of IL-2 activation. 
 Most of human MSC-mediated immunosuppressive function on alloantigen-activated 
T-lymphocyte proliferation was related to the secretion of anti-proliferative soluble factors 
(72;74;75;77;167). Recently, there is increasing evidence that the immunosuppressive effect 
of MSCs is not mediated by soluble immunosuppressive molecules only, but also may be 
mediated through cellular components of MLR e.g. subsets of T regulatory cells. However, 
the role of naturally occurring CD4
+
CD25
+
 T-regs in MSC-mediated immunosuppressive 
effect is still controversial. Krampera et al. (188) reported that MSCs induce a strong anti-
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proliferative effect not associated with any effect on enhancement of T regulatory activity. On 
the other hand, Maccario et al. (189) showed that lymphocyte populations containing variable 
proportions of putative CD4
+
CD25
+
 T-regs were obtained when MSCs were added to MLR, 
as a third party, at ratios of 1:1 and 1:2 MSC:MNC. Furthermore, Prevosto et al. (190) 
reported that powerful regulatory CD4
+
 or CD8
+
 lymphocytes are generated in co-cultures of 
MNCs with MSCs which may amplify the reported MSC-mediated immunosuppressive 
effect. In light of these controversial data we asked whether CD271-MSC cells use this 
additional mechanism to suppress alloantigen driven proliferation of MNCs in MLR. In 
contrast to the data of Maccario et al. (189) we found an increase in the percentage of 
CD4
+
CD25
high
 T regs as a result of allogeneic reaction on day 6 of MLR (from 3±2.2% on 
day 0 to 21.6±5.3% on day 6). In presence of CD271-MSCs the total number of 
CD4
+
CD25
high
 T regs on day 6 of MLR decreased significantly (8.5±1.9%) compared to the 
number of T regs in the wells where MNCs were cultured without MSCs (21.6±5.3%). 
Remarkably, flow cytometric analysis of these co-cultured MNCs with MSCs for 6 days 
revealed a significant increase of naïve CD4
+
CD25
high
CD45RA
+
CD62L
+
 T regs (66.5±4.7%,  
P<0.02) compared to the percentage of T regs in allogeneic MNCs cultured without MSCs 
(37.1±5.9%). Having in mind the evidence that only naïve T regs with this phenotype show a 
profound suppressive activity (191) and represent the only subset of T regs that protect mice 
from lethal acute GvHD (192), we presume that interactions between CD271-MSCs and 
alloantigen-activated lymphocytes promote a selective expansion of this subset of T regs, 
which may further propagate and extend the immunosuppressive effect of these MSCs. 
Taken together, we conclude that, unlike PA-MSCs, CD271-MSCs elicit a potent 
allosuppression even at lower concentrations and that the majority of immunossuppressive 
effect of CD271-MSCs is mediated via PGE2, but not via HLA-G, NO or IL-10 molecules. In 
addition, selective expansion of a subset of naïve T regulatory cells in presence of CD271-
MSC may further contribute to the suppression of alloantigen-activated lymphocytes. Based 
on the evidence that CD271-MSCs exert potent allosuppressive properties in vitro we suggest 
that these MSCs represent an unequivocal alternative to PA-MSCs for the treatment of 
patients with GvHD and other inflammatory disorders. 
 
5.4. The engraftment-promoting properties of CD271-MSCs 
 
An emerging body of evidence indicates that co-transplantation
 
of PA-MSC with human 
CD34
+
 cells facilitates their engraftment
 
and induces a shift in their differentiation from 
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predominantly
 
B lymphocytes to predominantly enhanced myelopoiesis (CD13
+, 
CD14
+
, and 
CD33
+
 cells) and megakaryocytopoiesis (193). We asked
 
whether CD271-MSC share the 
same properties with PA-MSC or may
 
be more efficient in modulating hematopoietic 
engraftment. Our
 
in vivo data revealed that co-transplantation of CD133
+
 cells
 
with CD271-
MSC significantly improved their multilineage engraftment
 
in the bone marrow of 
immunodeficient NOD/SCID mice at both
 
1:1 (about 10-fold) and 1:8 (about 23-fold) ratios 
in comparison
 
to transplantation of CD133
+
 cells alone. We found an approximately
 
2- to 3-
fold increase in the number of myeloid cells (CD33
+
)
 
and enhanced megakaryopoiesis 
(CD41a
+
), especially at the 1:8
 
ratio (about 2-fold more megakaryocytes); these findings 
indicate
 
the differentiation of CD133
+
 cells towards more primitive CD45
+
CD41a
+ 
megakaryocytes (194). In contrast to the above studies, however,
 
co-transplantation of 
CD133
+
 hematopoietic stem cells with CD271-MSC
 
at a ratio of 1:8 promoted their 
differentiation towards the
 
lymphoid lineage, in addition to megakaryopoiesis and 
myelopoiesis.
 
Remarkably, the number of CD3
+
 cells increased 10.4-fold (P<0.02),
 
the 
number of NK cells increased 2.5-fold (P<0.0007) and
 
the number of B cells increased 3.6-
fold (P<0.03), compared
 
to the group transplanted with CD133
+
 hematopoietic stem cells
 
and 
PA-MSC at the same ratio. In addition, CD271-MSC decreased
 
the number of CD56
+
 cells to 
approximately normal levels, whereas
 
in the control group an expansion of these cells was 
observed.
 
This finding is in agreement with data demonstrating that MSC
 
may alter the 
phenotype of NK cells and suppress proliferation,
 
cytokine secretion, and cytotoxicity against 
HLA class I-expressing
 
targets (195). Taken together, our data demonstrate that, in contrast
 
to 
PA-MSC, CD271-MSC are able not only to improve the engraftment
 
of hematopoietic stem 
cells, but also to promote their differentiation
 
into myeloid and lymphoid lineages. After co-
transplantation
 
with human CD34
+
 hematopoietic cells in children with hematologic
 
malignancies, PA-MSC induced a sustained engraftment that, nonetheless,
 
did not promote 
any significant T- or NK-cell recovery relative
 
to the control group transplanted with 
hematopoietic stem cells alone (196). Based on our findings, we assume that CD271-MSC 
offer a better alternative to PA-MSC for post-transplant T-cell reconstitution,
 
which 
substantially contributes to the successful outcome of hematopoietic stem cell transplantation. 
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5.5. Migratory potential of CD271-MSCs. 
 
Systemic delivery of MSC has been reported by several groups,
 
who found that the majority 
of cells were entrapped in the lungs
 
and a small amount engrafted in the heart, liver, and 
spleen (197;198). Data obtained from experiments in which CD271-MSCs or PA-MSCs
 
were 
individually transplanted into NOD/SCID mice via an intravenous
 
route revealed a similar 
organ distribution, with the majority
 
of the cells being entrapped in the lungs. When expanded 
CD271-MSC
 
or PA-MSC were co-transplanted with hematopoietic stem cells
 
at a ratio of 1:1, 
however, quantitative polymerase chain reaction
 
analysis for the human albumin gene 
demonstrated that the cells
 
migrated more efficiently to brain than to the lungs, liver,
 
heart, or 
skeletal muscle. In contrast, when co-transplanted
 
with hematopoietic stem cells at a ratio of 
8:1, CD271-MSC or
 
PA-MSC migrated mainly to the lungs and, to a much lesser extent,
 
to 
the liver, brain, heart, and skeletal muscle. Our data, therefore, suggest that not only can MSC 
influence hematopoietic stem cell
 
engraftment but also that hematopoietic stem cells may 
affect
 
the migration and homing pattern of MSC in vivo.
 
 
 
 
 
6. CONCLUSIONS 
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Based on the data obtained from this study we conclude that: 
 
1. The frequency of CD271+ bone marrow mononuclear cells (BM-MNCs) in our sample 
as assessed by flow cytometry was 0.6±0.1% (range, 0.2% to 1.2%; median
 
0.5%). 
 
2. The frequency of CD271+ BM-MNCs in our study varied from donor to donor and no 
correlation between this parameter and donor age was observed. 
 
3. Enriched CD271+ BM-MNCs generated a 26-fold higher number of CFU-Fs than 
compared to unselected BM-MNCs. 
 
4. In contrast to the CD271 negative cell fraction, only positively selected CD271+ BM-
MNCs gave rise to the CFU-Fs, suggesting that this cell fraction contains all 
progenitor cells for mesenchymal stromal cells (MSCs). 
 
5. No correlation between the number of CFU-Fs and the age of donors has been 
observed, most probably due to the small difference in the age of bone marrow donors 
included in this study (20-40 years old). 
 
6. Estimation of population doublings (PD) over a period of 30 days in culture revealed 
similar growth kinetics of both types of MSCs cultured either with FBS or with 
platelet lysate. 
 
7. Platelet lysate demonstrated equal stimulatory properties for proliferation of both 
CD271-MSCs and PA-MSCs as FBS. Our data therefore suggest that platelet lysate 
can be used as effectively as FBS in generating bulk quantities of MSCs under serum-
free conditions for a clinical application. 
 
8. CD271-MSC inhibited the mitogenic-induced proliferation of peripheral blood 
mononuclear cells (PB-MNCs) after stimulation
 
with concanavalin-A, 
phytohemagglutinin, or pokeweed mitogen at comparable levels with PA-MSCs. 
 
9. CD271-MSCs as well as PA-MSCs significantly suppressed the allogeneic reaction in 
vitro ranging from 40-80% of the maximal proliferation, as estimated by BrdU assay. 
 
10. The significant increase of prostaglandin E2 (PGE2) levels at co-incubation of 
CD271-MSCs with PB-MNCs at the ratio 1:1 or 1:2 (about 4.5-fold) correlated very 
well with the inhibitory effect of CD271-MSCs on allogeneic reaction in MLR at 
these ratios. 
 
11. Indomethacin, an inhibitor of cyclooxygenase-1 necessary for the biosynthesis of 
PGE2, mitigated the overall suppressive effect of CD271-MSCs on proliferation of 
PB-MNCs when co-cultured at ratio 1:1, suggesting that PGE2 represents one of the 
major mediators of this effect. 
 
12. On the other hand, indomethacin was not able to reverse the inhibitory effect of 
CD271-MSCs when these MSCs were co-incubated with MNCs at 1:2 or 1:10 ratio, 
suggesting that PGE2 does not affect the MSCs-mediated immunosuppression when 
allogeneic MNCs are in excess. 
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13. Estimation of the levels of soluble HLA-G or nitric oxide in the supernatants of MLR 
demonstrated that none of these molecules is responsible for the MSC-mediating 
immunosuppression in vitro. 
 
14. CD271-MSCs in co-culture with allogeneic MNCs, were able to significantly decrease 
concentration of IFN-gamma (about 80%) and TNF-alpha (about 90%) in MLR at 
both 1:1 and 1:2 ratio, indicating their strong anti-inflammatory effect. However, no 
increase of IL-10 levels was observed. 
 
15. In presence of CD271-MSCs the total number of CD4+CD25high T regulatory cells on 
day 6 of MLR decreased significantly (about 2.5-fold) compared to the number of T 
regs in the wells where MNCs were cultured without MSCs. 
 
16. Flow cytometric analysis of co-cultured CD271-MSCs with MNCs for 6 days revealed 
a significant increase (about 2-fold) of naïve CD4
+
CD25
high
CD45RA
+
CD62L
+
 T regs, 
indicating that this subset of T regs may extend the immunosuppressive acitivity of 
CD271-MSCs. 
 
17. Our in vivo data revealed that co-transplantation of CD133+ hematopoietic stem cells 
with CD271-MSC significantly improved the overall engraftment
 
in the bone marrow 
of immunodeficient NOD/SCID mice at both
 
1:1 (about 10-fold) and 1:8 (about 23-
fold) ratios in comparison
 
to transplantation of CD133
+
 cells alone. 
 
18. After co-transplantation with CD271-MSCs at 1:1 ratio, CD133+ hematopoietic stem 
cells gave rise to approximately
 
2- to 3-fold more myeloid cells (CD33
+
)
 
and more 
primitive CD45
+
CD41a
+ 
megakaryocytes. 
 
19. Remarkably, co-transplantation of CD133+ hematopoietic stem cells with CD271-
MSC
 
at a ratio of 1:8 promoted their differentiation not only towards myelopoiesis, 
but also to the
 
lymphoid lineage. This represents a substantial qualitative difference 
between CD271-MSCs and PA-MSCs. 
 
20. Migration studies as evaluated by the quantitative polymerase chain reaction analysis 
for the human albumin gene demonstrated a characteristic distribution of MSCs in 
transplanted mouse organs. When CD271-MSCs were co-transplanted with CD133
+
 
cells at ratio 1:1 most of the MSCs were found in the brain, in contrast to the 
MSC:CD133
+
 ratio 8:1, whereby most of these MSCs were entrapped in the lungs. 
 
21. Taken together, our results indicate that CD271 antigen provides a versatile marker for 
prospective isolation and expansion of multipotent
 
mesenchymal stromal cells with 
immunosuppressive and lymphohematopoietic
 
engraftment-promoting properties. The 
co-transplantation of
 
such cells together with hematopoietic stem cells in patients
 
with 
hematologic malignancies may prove valuable in the prevention
 
of impaired/delayed 
T-cell recovery and graft-versus-host disease. 
 
 
 
7. SUMMARY 
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OBJECTIVE. In vitro proliferative and differentiation potential of mesenchymal stromal 
cells (MSCs) generated from CD271
+
 bone marrow mononuclear
 
cells (CD271-MSCs) has 
been demonstrated
 
in several earlier and recent reports. In the present study
 
we focused, in 
addition to proliferative and differentiation
 
potential, on in vitro and in vivo 
immunosuppressive and lymphohematopoietic
 
engraftment-promoting potential of these 
mesenchymal stromal
 
cells compared to bone marrow-derived mesenchymal stromal cells
 
generated by plastic adherence (PA-MSCs). 
 
MATERIALS AND METHODS. We set up a series of experimental protocols in 
order to determine
 
the phenotype of bone marrow-derived CD271-MSCs, their
 
clonogenic, 
proliferative, differentiation and immunosuppressive
 
potential. The potential of CD271-MSCs 
to improve the engraftment of CD133
+
 hematopoietic stem cells
 
at co-transplantation was 
evaluated in immunodeficient NOD/SCID-IL2R
null
 mice. 
 
RESULTS. In vitro studies demonstrated that CD271-mesenchymal stromal cells 
differentiate along adipogenic, osteogenic and chondrogenic
 
lineages (trilineage potential), 
and significantly inhibit the proliferation of allogeneic
 
T-lymphocytes in mixed lymphocyte 
reaction assays. Elevated
 
levels of prostaglandin E2, but not nitric monoxide, IL-10 or soluble 
HLA-G, mediated
 
the majority of this immunosuppressive effect. In vivo studies
 
showed that 
CD271-mesenchymal stromal cells promoted significantly
 
greater lymphoid engraftment than 
did PA-MSCs when co-transplanted with CD133
+
 hematopoietic
 
stem cells at a ratio of 8:1 in 
immunodeficient NOD/SCID-IL2R
null
 mice. They induced a 10.4-fold increase in the 
number of
 
T cells, a 2.5-fold increase in the number of NK cells, and
 
a 3.6-fold increase in the 
number of B cells, indicating a major
 
qualitative difference between these two mesenchymal 
stromal
 
cell populations. 
 
CONCLUSIONS. Our results indicate that CD271 antigen provides a versatile marker for 
prospective isolation and expansion of MSCs with immunosuppressive and 
lymphohematopoietic
 
engraftment-promoting properties. The co-transplantation of
 
such cells 
together with hematopoietic stem cells in patients
 
with hematologic malignancies may prove 
valuable in the prevention
 
of impaired/delayed T-cell recovery and graft-versus-host disease. 
 
 
8. SAŽETAK 
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SVRHA I CILJ RADA. In vitro proliferacijski i diferencijacijski potencijal 
mezenhimskih stromalnih stanica podrijetlom od CD271
+
 mononuklearnih stanica koštane 
srži (CD271-MSS) pokazan je u nekoliko nedavno objavljenih radova i izvješća. U ovom smo 
se radu, pored proliferacijskog i diferencijacijskog potencijala tih mezenhimalnih stromalnih 
stanica fokusirali na njihov in vitro i in vivo imunosupresijski potencijal i potencijal za 
promociju prihvaćanja limfohematopoetskog presatka u odnosu na mezenhimske stromalne 
stanica podrijetlom iz koštane srži koje su proizvedene adherencijom na plastiku (PA-MSS).  
MATERIJAL I METODE. U radu smo postavili niz eksperimentalnih protokola u cilju 
određivanja fenotipa CD271-MSS podrijetlom iz koštane srži, kao i njihov klonogeni, 
proliferacijski, diferencijacijski i imunosupresijski potencijal. Potencijal CD271-MSS za 
promociju prihvaćanja CD133+ krvotvornih matičnih stanica nakon njihove kotransplantacije 
ispitan je u modelu imunodeficijentnih miševa NOD/SCID-IL2Rγnull. 
REZULTATI. In vitro pokusi pokazali su da se CD271-mezenhimske stromalne stanice 
diferenciraju u adipogenu, osteogenu i hondrogenu liniju (trilinijski potencijal) te značajno 
inhibiraju proliferaciju alogeničnih limfocita T u reakciji pomiješanih limfocita. Glavnina 
imunosupresijskog učinka posredovana je povećanom razinom prostaglandina E2, a ne 
dušičnim monoksidom (NO), interleukinom-10 (IL-10) ili topljivim molekulama HLA-G. 
Pokusi in vivo pokazali su da CD271-mezenhimske stromalne stanice značajno bolje 
promoviraju prihvaćanje limfoidnih stanica nego li PA-MSS nakon kotransplantacije s 
CD133+ krvotvornim matičnim stanicama u odnosu 8:1 u imunodeficijentne miševe 
NOD/SCID-IL2Rγnull. Pri tome CD271-MSS uzrokuju povećanje broja limfocita T za 10,4x,  
povećanje broja NK-stanica za 2,5x, kao i povećanje broja B-stanica za 3,6x, što ujedno i 
predstavlja glavnu kvalitativnu razliku između te dvije populacije mezenhimskih stromalnih 
stanica.  
ZAKLJUČCI. Naši rezultati pokazuju da antigen CD271 predstavlja pogodan biljeg za 
prospektivno izdvajanje i ekspanziju mezenhimskih stromalnih stanica koje posjeduju 
imunosupresijski potencijal i promoviraju prihvaćanje limfohematopoetskog presatka. 
Kotransplantacija CD271-MSS zajedno s krvotvornim matičnim stanicama u bolesnika s 
malignim hematološkim bolestima može se pokazati korisnim za sprečavanje poremećaja ili 
odgođenog oporavka limfocita T, kao i za sprečavanje bolesti zbog reakcije presatka na 
domaćina (graft-versus-host disease). 
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